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Chronic skin diseases are known to be common among the general population. 
Nevertheless, little research attention has been paid to patients with skin diseases 
in the general population, and consequently, little is known about the impact of 
skin diseases on daily life within this population. General definitions of health 
encompass different dimensions of disease outcome divided in disease severity, 
accompanying physical symptoms, and psychosocial well-being (see figure 1)1,2. 
These dimensions of health influence the impact of a disease on daily life. So 
far, research on disease outcome has primarily focused on skin diseases most 
frequently encountered on dermatological wards, such as atopic dermatitis or 
psoriasis, leaving unaddressed many types of skin conditions and patients not seen 
on dermatological wards. Moreover, studies usually examine disease outcome at 
times when patients contact their health care provider, which is presumably when 
symptoms are worse, which might in turn lead to biased conclusions about the 
general impact of skin diseases on patients in daily life. 
Figure 1. Dimensions of disease outcome
Although in general disease outcome is assumed to interact with psychological 
factors2, few attempts have been made to investigate psychological factors 
associated with disease outcome in patients with skin diseases. Consequently, the 
role of specific psychological factors in the maintenance and exacerbation of skin 
diseases is unclear. 
Among the general population, approximately 3% of people with health 
complaints visit a hospital clinic while more than 10% visit a general practitioner3, 
which suggests that findings from hospital wards do not automatically apply to 
general practice. Research conducted within both settings is necessary to examine 
the impact and clinical relevance of skin diseases in these settings. The present 
thesis examines skin diseases both in general practice and on dermatological wards. 
First, the impact of skin diseases on general practice patients was investigated 
(chapter 2.1, 2.2 and 2.3) with emphasis on disease outcome according to general 
models of health (see figure 1). Then, this thesis evaluates the influence of 
psychological factors on disease outcome in patients with chronic skin diseases 
Disease outcome
	 •	Disease	severity
	 •	Physical	symptoms
	 •	Psychological	and	social	well-being
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seen on dermatological wards. After a general review (chapter 3.1), this thesis 
particularly emphasizes on patients with psoriasis (chapter 3.2 and 3.3). 
Impact of skin diseases on patients in general practice 
Since the first morbidity analyses, it has been known that skin diseases account 
for about 10% of all diseases seen by general practitioners in the Netherlands. 
Particularly, the prevalence of e.g. atopic dermatitis, psoriasis, acne vulgaris, and 
warts is reported to be high in general practice. Moreover, the prevalence of some 
specific skin diseases (e.g. atopic dermatitis and carcinoma of the skin) is reported 
to be increasing4-6, which makes it essential to have ongoing up-to-date information 
about the prevalence of skin diseases. Besides the prevalence of a disease, the 
use of health care resources and patient characteristics also influence the impact 
of a disease on society. Knowledge about these factors may help health care 
providers manage skin diseases in daily practice. For example, knowledge about the 
prevalence of a disease indicates the likelihood of occurrence of a specific disease 
within a patient sample. In addition, knowledge of these factors may be used to gain 
insight into the economic cost of diseases. For the individual impact of a disease, 
the dimensions of disease outcome (see figure 1) are essential, and can benefit 
from patients’ treatment. For example, information about the physical symptoms 
associated with a disease or the impact of the disease on psychosocial well-being 
facilitates early detection and treatment. The impact of a disease can be measured 
in different patient samples (e.g. general practice, on a dermatological ward) and 
at different points in time (e.g. when patients visit their health care provider or at a 
random moment independent of their visits to health care providers), and may differ 
by the type of disease. To date, the impact of skin diseases has been investigated 
mainly in terms of skin diseases frequently seen on dermatological wards, such as 
psoriasis and atopic dermatitis. Consequently, there is little information about a 
large number of patients with skin diseases who are not admitted to hospital wards 
and who may have less common skin conditions. 
Itch is a common physical symptom of many skin diseases7, but less is 
known about physical symptoms accompanying skin diseases, such as pain or 
fatigue, which have been described in patients on dermatological wards8,9. Studies 
about the psychosocial impact of skin diseases conducted on dermatological wards 
have shown that patients with skin diseases such as atopic dermatitis, psoriasis, 
or acne vulgaris have a lower well-being than the general population10-12. The 
psychosocial consequences of skin diseases in general practice have been studied 
only incidentally13. Given that the general practice population may differ from that 
of dermatological wards, there may also be differences in psychosocial well-being 
between the two populations. 
Biopsychosocial predictors of disease outcome in patients with skin 
diseases
Most attention has been paid to the clinical judgement of the severity of skin 
diseases as main indicator of disease outcome. However, itch is a common 
symptom of many skin diseases7. Although several medical treatments regarding 
itch are available, so far none is completely effective14. Besides underlying 
biological pathology, psychological factors have also been associated with both 
disease severity and itch15,16, and psychological interventions can contribute 
to the management of both17. In contrast to the traditional biomedical model, 
the involvement of psychological factors in chronic skin diseases supports a 
biopsychosocial model. Biopsychosocial factors can best be shown in a stress-
vulnerability model, which is based on the hypothesis that internal vulnerability 
factors (e.g. personality) and external environmental factors (e.g. stressors) affect 
disease outcome. In this model, psychological factors can be considered to mediate 
or moderate this relationship (Figure 2). 
To investigate whether internal factors such as personality and external 
environmental factors such as stressors influence disease outcome in patients with 
skin diseases, it is necessary to determine whether these factors are associated with 
changes in disease outcome over time. For this purpose, prospective studies are 
required. So far, there have been few of such studies in patients with skin diseases.
Figure 2. Biopsychosocial model of chronic skin diseases
The influence of a stressor on disease outcome may be partially explained 
by patients’ individual reaction to this stressor. It has been shown that patients 
with psoriasis who consider their psoriasis to be reactive to stressors have higher 
Internal factors:
	 •	Personality	
Psychological mediating   
or moderating factors:
 Cognitive factors e.g.
	 	 •	Worrying
 Behavioral factors e.g.
	 	 •	Scratching
	 	 •	Avoidance	behavior
 Social factors e.g.
	 	 •	Perceived	support
	 	 •	Social	network
Physiological factors:
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	 •	Endocrine
	 •	Immunological
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scores on measures of disease outcome than patients who consider themselves less 
reactive18;19. Also, the effect of social support on the relationship between stressors 
and disease outcome is a well-known example of the influence of psychological 
factors. Stressors might unfavorably affect disease outcome only in the event of low 
levels of social support. Consequently, psychological factors, such as individual 
reactivity to a stressor and social support, could influence the relationship between 
the experience of stressors and disease outcome in patients with skin diseases. 
Regarding psychological factors of individual reactivity to a stressor, the 
cognitive factor of e.g. perseverative worrying is a common response to disease or 
stressful events and has been reported to prolong stress-related activation of, for 
example, endocrine and immunological systems20. Consequently, worrying could 
influence physical well-being through several psychological and physiological 
pathways. In patients with psoriasis, worrying has indeed been shown to negatively 
influence disease severity and itch, particularly in patients with high levels of 
worrying 9,21. Specifically for itch, scratching is an important behavioral factor in the 
stress-vulnerability model, as reflected by the definition of itch as an unpleasant 
sensation that evokes the desire to scratch22. Due to a vicious itch-scratch-itch 
cycle, scratching may negatively affect disease outcome and become a problem in 
its own right. Additionally, in line with other chronic conditions, such as chronic 
pain23-27, behavioral factors, such as enduring patterns of avoidant behavior, have 
been shown to affect outcome in patients with skin diseases15,28. Although the acute 
effects of the symptoms of skin diseases (e.g. itch) predominantly trigger patients 
to become physically active (for example by provoking scratching), the long-term 
behavioral response usually causes patients to withdraw from activities or to avoid 
daily activities in order to prevent an exacerbation of symptoms. 
As shown in figure 2, physiological factors may have an important role in 
predicting disease outcome. Several pathways may be involved in this process. 
For example, the hypothalamic–pituitary-adrenal axis (HPA axis) is a particularly 
important and frequently described component of the body’s stress system. One of 
the main functions of this axis is to maintain basal and stress-related homeostasis. 
External stressors can activate this stress response system in the brain, and the 
hormones of the HPA axis in turn activate mast cells in the skin to degenerate. 
Degeneration of mast cells causes the release of several prestored mediators 
of itch, such as histamine, serotonine, substance P, or interleukin-6 (IL-6)29,30. 
Furthermore, the HPA axis has several feedback loops with the immune system in 
which the secretion of glucocorticoids is particularly important. Glucocorticoids 
inhibit inflammatory responses and suppress the production and release of pro-
inflammatory cytokines of the immune system31,32. Pro-inflammatory cytokines 
in particular have been associated with the severity of chronic inflammatory 
diseases such as psoriasis33. Finally, stressors can induce autonomous responses 
such as increased muscle tension and transpiration, which can also worsen the 
itch sensation34,35. Psychological processes may influence all these physiological 
pathways. However, knowledge about such relationships among patients with skin 
diseases is limited. 
Purpose and outline of the thesis 
The thesis consists of two main parts. The first part (chapter 2.2, 2.2, and 2.3) 
describes studies of the impact of skin diseases among general practice. The 
second part (chapter 3.1, 3.2, and 3.3) describes studies performed to examine 
biopsychosocial predictors of disease severity and itch among patients seen on 
dermatological wards. 
The first part starts with a description of the prevalence of skin disease 
in general practice (chapter 2.1). In the Netherlands, the general practitioner 
is a gatekeeper for more specialized care, and for this reason Dutch general 
practitioners encounter a broad spectrum of different diseases. Data from general 
practice are therefore extremely suitable to gain insight into the occurrence of 
diseases in the general population. At the Radboud University Medical Centre, 
the Department of General Practice has kept a Continuous Morbidity Registration 
(CMR) of all diseases seen by general practitioners since the 1970s. The registration 
covers a relatively stable population of 12 000 citizens that is representative of the 
general Dutch population. For the purposes of the present studies, data from the 
CMR were used in combination with information obtained by questionnaires sent 
to patients aged 18 years or older who had been registered with a skin disease 
within this CMR during the preceding 12 months. These questionnaires provided 
information about the use of health care facilities (chapter 2.1), the experience of 
accompanying physical symptoms of itch, pain, and fatigue (chapter 2.2) and the 
psychological and social well-being of patients with skin diseases (chapter 2.3).
The second part starts with a review of the evidence for a biopsychosocial 
model of chronic itch in patients with skin diseases (chapter 3.1). Next, aspects 
of this model were examined within two groups of patients, namely, those with 
atopic dermatitis and those with psoriasis (chapter 3.2). For this purpose, cognitive, 
behavioral, and physiological reactivity as predictors of disease outcome were 
examined. Finally, a prospective study of patients with psoriasis investigating the 
influence of psychological factors on changes in disease severity and itch was then 
performed (chapter 3.3). In this study, patients were followed up for six months, 
during which the experience of daily stressors and cognitive and behavioral factors 
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were assessed monthly together with monthly clinical and self-reported measures of 
disease severity and itch. 
The results of the studies are presented in chapter 2 and chapter 3, and are 
summarized in chapter 4. The main findings are then discussed in chapter 5.
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Abstract
Background
Ongoing care for people with skin diseases can be optimized by understanding 
the incidence and population prevalence of various skin diseases and the patient-
related factors (e.g. disease severity, psychosocial well-being) related to the use of 
primary, specialty, and alternative health care for these conditions. 
Objective
The present study examined the recent prevalence of skin diseases in a defined 
population of patients within general practice, self-reported disease-related quality 
of life, extent and duration of skin disease, as well as the use of health care by 
patients with skin diseases. 
Methods
A morbidity registry- based epidemiological study to determine the prevalence of 
various skin diseases, and a patient questionnaire about the use of health care were 
undertaken within a network of general practices in the Netherlands (Continuous 
Morbidity Registration) with a practice population of approximately 12,000 citizens. 
Results
Skin diseases accounted for 12.4% of all diseases seen by the participating general 
practitioners. Of the 857 questionnaires sent to patients registered with a skin 
disease, 583 (68.0%) were returned and 501 were suitable for analysis. In the 
previous year, 82.8% of the patients had contacted their general practitioner for 
their skin disease, 17.6% a specialist, and 5.0% had consulted an alternative health 
care practitioner. Overall, 65% contacted only their general practitioner. Patients 
who reported a significantly higher skin disease severity and a lower quality of life 
made more use of all forms of health care.
Conclusion 
This practice population-based study reveals that skin diseases account for 12% of 
diseases seen by general practitioners, and that some skin problems (e.g. chronic 
and more severe diseases) may be presenting more frequently. While particularly 
patients with more extensive skin diseases also obtain care from dermatologists, 
most patients with skin diseases are mainly treated by their general practitioner. 
Overall, patients with more severe disease severity and a lower quality of life seek 
more treatment.  
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Introduction
Ongoing care for people with skin diseases can be optimized by understanding 
the incidence and population prevalence of various skin diseases and the patient-
related factors (e.g. disease severity, psychosocial well-being) related to the use of 
primary, specialty, and alternative health care for these conditions. Although it has 
been reported that skin disease are common among the general population and 
account for a high percentage of all diseases dealt with by general practitioners1-8, 
recent prevalence data are essential considering the reported increase in the 
prevalence of specific skin diseases (e.g. atopic dermatitis and carcinoma of the 
skin)9-11 Additionally, the use of health care facilities by patients with skin diseases 
has rarely been investigatede.g.1,2,12.
The goal of the present study was to examine the prevalence of skin 
diseases and the health care facilities use by patients with skin diseases. 
Additionally, the relationship between this use of health care facilities and disease-
related variables (e.g. disease-severity and quality of life) was investigated. In 
addition to exploring the recent prevalence of skin diseases, we expected more 
health care facilities use in patients with more severe skin diseases and a lower 
quality of life. 
Methods
The Continuous Morbidity Registration (CMR)
This research was conducted within the CMR of the Department of General Practice 
of the Radboud University Nijmegen Medical Centre, the Netherlands13-16. The CMR 
was founded in 1971, consists of four general practices and 11 general practitioners 
(GP), and records all new episodes of diseases presented to general practitioners 
participating in the network. Consequently, the CMR is a diagnosis-based disease 
registration in which diagnoses are recorded according to the adapted E-list17,18, 
which is compatible with the International Classification of Health Problems in 
Primary Care (ICHPPC-2)19. In the Netherlands each person is registered with 
one GP, who is a gatekeeper of access to specialist medical care. This enables 
the CMR to register referrals to medical specialists and the specialist-reported 
diagnoses as well. The CMR network covers a relatively stable practice population of 
approximately 12,000 citizens, which are representative in terms of age and gender 
for the general Dutch population. All patients are informed about the use of the 
database and asked to provide written consent.
Prevalence and incidence
Within the registration, the age- and gender-specific prevalence of the skin diseases 
seen over a five-year period (2002-2006) was calculated as well as the incidence (all 
new cases) over the same period of time. 
Use of health care facilities
Questionnaires were sent to all patients aged 18 years or older registered with 
commonly encountered skin diseases during the 12 months preceding the 
questionnaire study. The questionnaire was administered at a random moment in 
time and not necessarily when the patients visited their GP, a time when the skin 
disease is presumably more active. 
Health care facilities use was measured by the number of contacts (visits, telephone 
calls for prescriptions, or contact for referrals) with the GP for skin diseases in 
the previous year. Additionally, the number of contacts with other specialists and 
complementary or alternative medicine practitioners in the previous year was 
assessed. 
Disease severity was assessed with a validated nine-item disease severity scale 
from the ISDL measuring the degree to which nine parts of the body (face, haired 
head, neck, hands, arms, torso, legs, feet, and genitals/ anus) were affected by the 
disease, with response categories on a four-point Likert scale ranging from “not” (1) 
to “totally” (4)20,21. A total score (range 9-36) for the affected area of the body was 
calculated by summing the scores of the nine items. 
Physical symptoms of itch, pain, and fatigue were assessed with separate Visual 
Analogue Scales (VAS) measuring the mean level of itch, pain, and fatigue over 
the past four weeks (0 = no itch/pain/fatigue; 10 = worst itch/pain/fatigue ever 
experienced)20,21.
Disease-related quality of life was measured with the Dermatological Life Quality 
Index22. Higher scores indicate a lower disease-related quality of life.
Disease duration was measured as the self-reported time since initial diagnosis in 
years.
Results
Prevalence and incidence
Within the CMR, skin diseases accounted for 12.4% of all diseases seen by the 
participating general practitioners. By calculating the amount of skin diseases in 
the percentage of all diseases instead of the percentage of all patients, one gains a 
more precise insight in the frequency that general practitioners encounter a disease. 
Table 1 shows the age- and gender-specific prevalence and incidence of each skin 
disease. 
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Table 1. Prevalence and incidence over the years 2002-2006 per 1000 patient-years*,  
by age and gender
Inc incidence M male
Prev prevalence F female
Skin disease  Total M F M F M F 
   total total 0-4 0-4 5-14 5-14
Acne vulgaris Inc 3.2 2.4 4.1 0.4 0.4 5.6 6.6
 Prev 9.6 5.4 13.7 0.4 0.4 7.2 8.6
        
Atopic dermatitis Inc 6.1 6.5 5.7 56.4 40.4 7.4 6.2
 Prev 24.8 23.8 25.7 108.9 77.8 49.9 35.0
        
Benign neoplasm Inc 17.5 14.0 20.8 1.2 1.7 2.5 4.4
 Prev 17.6 14.0 21.0 1.2 1.7 2.5 4.4
        
Chronic ulcur Inc 2.1 1.7 2.5 0.0 0.0 0.0 0.0
 Prev 2.5 2.2 2.8 0.0 0.0 0.0 0.0
        
Contact dermatitis Inc 2.5 1.5 3.5 0.4 0.8 1.1 1.3
 Prev 4.0 2.2 5.8 0.4 0.8 1.1 1.5
        
Corns Inc 3.9 3.4 4.4 0.4 0.0 0.4 0.7
 Prev 4.0 3.4 4.5 0.4 0.0 0.4 0.7
        
Dermatitis Inc 53.9 44.0 63.4 62.7 61.0 31.2 41.0
 Prev 64.7 53.4 75.3 64.3 61.4 32.6 43.2
        
Diseases of the hair Inc 1.5 0.8 2.1 0.4 0.0 0.7 1.3
 Prev 2.5 1.4 3.7 0.4 0.0 0.9 1.3
        
Diseases of the nails Inc 6.8 6.0 7.5 2.4 3.4 4.7 9.3
 Prev 6.8 6.1 7.5 2.4 3.4 4.7 9.3
        
Diseases of sebaceous  Inc 1.8 1.5 2.1 1.2 0.4 0.4 2.6
glands and sweat glands Prev 1.9 1.6 2.1 1.2 0.4 0.4 2.6
 M F M F M F  M F M F 
 15-24 15-24 25-44 25-44 45-64 45-64 65-74 65-74 75+ 75+
 13.3 17.3 0.9 4.9 0.0 0.0 0.0 0.4 1.5 0.0
 35.0 66.9 3.0 18.8 0.2 1.7 0.0 0.4 1.5 0.0
         
 2.5 8.4 2.0 2.7 0.9 1.7 0.4 1.1 0.7 0.4
 18.7 40.6 11.9 22.8 7.6 11.0 11.3 18.2 10.4 11.3
         
 7.9 16.1 18.4 25.5 19.3 32.1 17.9 23.35 14.2 11.3
 7.9 16.1 18.4 25.5 19.3 32.4 17.9 24.4 14.2 11.3
         
 0.0 0.0 0.5 0.3 1.5 1.0 5.0 3.6 18.7 27.9
 0.0 0.0 0.6 0.3 1.8 1.0 5.8 3.6 27.6 32.7
         
 2.2 7.1 1.8 4.3 1.2 4.0 0.8 2.5 3.7 1.3
 3.2 8.7 2.3 7.0 2.4 7.7 2.9 3.6 3.7 4.4
         
 2.2 2.2 3.9 4.0 4.1 5.5 5.0 8.4 10.4 13.1
 2.2 2.2 3.9 4.2 4.1 5.5 5.0 8.4 10.4 13.1
         
 30.2 65.3 35.0 59.3 45.2 66.5 67.1 82.9 100.7 92.0
 31.5 75.5 42.1 67.0 57.6 84.5 89.6 106.5 147.7 119.9
         
 0.6 2.2 1.1 3.3 0.9 2.3 0.0 0.7 0.7 0.9
 0.6 2.2 2.0 4.1 1.8 3.9 0.4 7.6 0.7 6.5
         
 13.3 8.7 6.6 7.9 4.8 6.0 5.0 8.0 5.2 10.5
 13.3 8.7 6.7 7.9 5.0 6.0 5.0 8.0 5.2 10.5
         
 2.5 4.3 2.1 2.5 1.2 1.6 1.7 0.7 1.4 0.9
 3.2 4.3 2.2 2.5 1.3 1.6 1.7 0.7 1.4 0.9
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Table 1 continued. Prevalence and incidence per 1000 patient-years, by age and gender.
Inc incidence M male
Prev prevalence F female
* The use of patient-years is necessary in long-term follow-up research because not every patient under study 
can be observed for the same period of time (due to e.g. death). The total number of patient-years in the 
registration is the sum of the observation period for all observed individuals. In this case, each month within 
the five-year period that a patient could be observed counts for 1/12 patient year in the total number of 
patient years in the network.
Skin disease  Total M F M F M F 
   total total 0-4 0-4 5-14 5-14
Melanoma Inc 0.2 0.2 0.3 0.0 0.0 0.0 0.0
 Prev 1.7 1.0 2.4 0.0 0.0 0.0 0.0 
       
Pruritus Inc 2.1 1.7 2.4 0.0 0.0 1.1 0.9 
 Prev 2.2 19 2.5 0.0 0.0 1.1 0.9 
       
Psoriasis Inc 1.5 1.3 1.6 0.0 0.4 0.4 0.4 
 Prev 15.9 15.5 16.4 0.0 0.4 0.9 0.7
        
Sebaceous cyst Inc 10.8 11.2 10.4 0.4 0.4 2.5 0.9 
 Prev 10.8 11.2 10.4 0.4 0.4 2.5 0.9 
       
Seborrheic dermatitis Inc 5.8 5.0 6.5 3.6 7.6 3.8 2.4
 Prev 12.9 12.8 13.0 3.6 7.6 5.4 4.0
        
Seborrheic keratosis    Inc 7.2 6.2 8.1 0.0 0.0 0.2 0.0
(Wart seborrheic) Prev 7.2 6.3 8.1 0.0 0.0 0.2 0.0 
       
Squamous cell Inc 0.4 0.5 0.3 0.0 0.0 0.0 0.0
cercinoma Prev 0.6 0.8 0.5 0.0 0.0 0.0 0.0
 M F M F M F  M F M F 
 15-24 15-24 25-44 25-44 45-64 45-64 65-74 65-74 75+ 75+
 0.0 0.0 0.1 0.3 0.2 0.6 0.4 0.7 0.7 0.4
 0.0 0.0 0.5 2.2 1.7 4.8 2.1 2.5 6.0 5.2
         
 0.3 0.9 0.6 2.0 2.4 3.1 3.8 2.2 9.7 10.0
 0.3 1.2 0.6 2.2 3.0 3.1 4.6 2.2 9.7 10.0
         
 1.9 0.9 1.5 1.9 1.4 2.2 1.7 1.5 2.2 3.1
 3.8 7.7 13.0 12.8 21.0 20.0 46.2 39.3 46.3 51.9
         
 6.7 9.3 15.1 12.4 14.9 13.8 11.3 15.6 17.2 11.8
 6.7 9.3 15.1 12.4 15.0 13.8 11.3 15.6 17.2 11.8
         
 3.5 5.6 3.8 6.4 6.3 6.9 9.2 6.2 9.0 13.5
 7.0 9.0 8.9 11.7 17.4 16.7 20.8 14.9 53.7 31.8
         
 0.3 0.3 2.9 3.7 12.2 16.3 14.6 19.3 21.6 18.7
 0.3 0.3 2.9 3.7 12.2 16.3 15.0 19.3 21.6 18.7
         
 0.0 0.3 0.0 0.0 0.2 0.3 2.9 0.4 4.5 1.7
 0.0 1.5 0.0 0.0 0.4 0.5 5.4 0.7 6.0 3.5
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Table 2. Comparison of patients who visited a health care provider with those who did not 
(Student’s t-test).
a 0 = male, 1 = female, compared through Pearson’s chi square.
b as measured by the ISDL, ranging from 9-36.
c assessed with Visual Analogue Scales: 0 = no itch/pain/fatigue; 10 = worst itch/pain/fatigue ever experienced.
dDermatological Life Quality Index: higher scores indicate a lower disease-related quality of life
Use of health care facilities
Of the 857 questionnaires sent, 583 (68.0%) were returned. The questionnaires of 
501 patients were suitable for analysis. The mean age of these patients was  
49.7 years (SD 17.1, range 18.5 - 97.6), 60.9 % were female, and 7.4%, 60.9%, and 
31.7% had a primary, secondary, and tertiary level of education, representing on 
average 7, 12, and 17 years of formal education. There was no gender difference 
between the responders and non-responders, but the responders were significantly 
younger (t = 3.9; p < 0.01). Completed questionnaires were returned by the 
following number of patients: 41 acne vulgaris, 97 atopic dermatitis, 27 contact 
dermatitis, 11 corns, 67 dermatitis, 11 diseases of sebaceous glands and sweat 
glands, 115 psoriasis, 72 seborrheic dermatitis, and 29 seborrheic wart. Fewer 
than 10 patients with diseases of the nail, sebaceous cyst, benign neoplasm of the 
skin, chronic ulcer, pruritus, diseases of the hair and the different forms of skin 
carcinoma could be included in our analyses. The mean duration of skin disease was 
16.7 years (SD 15.5, range 0.1-67.1).
Of the 501 patients who returned the questionnaire, 83.4% reported having 
contacted their GP for their skin disease in the previous 12 months (62.1% for visits 
with a mean of 2.8 office visits, 46.3% for prescriptions with a mean of  
3.1 phone calls and 9.4% for referral to other specialists with a mean of 1.4 
contacts). Seventeen percent of the patients had visited a specialist, on average  
3.7 times (91.3% visited a dermatologist). In addition, 5.2% had visited an 
alternative health care practitioner (on average 8.1 times). 
Analysis of the possible combinations of health care facilities use showed 
that most patients merely contacted their GP (n = 326, 65.1%). Eight (1.6%) and 
 Contact general practitioner
 Yes (n=417) No (n=84) 
 M(SD) M(SD) p-value
   
Age 49.7(17.5) 49.7(15.1) NS
Gender a  0.6(0.5) 0.6(0.5) NS
Educational level 4.3(2.0) 4.2(2.0) NS
   
Disease severity b  12.5(2.8) 11.2(2.4) <0.01
Disease duration (in years) 16.7(15.6) 17.7(14.7) NS
   
Itch c  3.4(2.7) 2.0(2.3) <0.01
Pain c  1.6(2.0) 1.2(1.7) <0.05
Fatigue c 3.2(2.8) 2.5(2.6) <0.05
   
DLQI d 4.3(4.9) 2.4(3.8) <0.01
 Contact specialist Contact alternative health practitioner
 Yes (n=85) No (n=416)  Yes (n=26) No (n=475) 
 M(SD) M(SD) p-value M(SD) M(SD) p-value
     
 50.1(19.2) 49.6(16.7) NS 40.3(13.3) 50.2(17.1) <0.01
 0.7(0.5) 0.6(0.5) NS 0.8(0.4) 0.6(0.5) NS
 4.2(2.0) 4.3(2.0) NS 4.8(2.0) 4.3(2.0) NS
     
 13.3(3.3) 12.1(2.6) <0.01 14.0(3.1) 12.2(2.7) <0.01
 15.6(17.6) 17.1(15.0) NS 21.3(14.4) 16.1(15.5) NS
     
 3.9(3.0) 3.0(2.6) <0.05 4.8(2.8) 3.0(2.6) <0.01
 1.9(2.2) 1.5(1.9) NS 2.7(2.7) 1.5(1.9) <0.05
 3.3(3.0) 3.1(2.8) NS 4.3(2.8) 3.0(2.8) <0.05
     
 5.6(5.6) 3.7(4.5) <0.01 10.3(7.3) 3.7(4.3)) <0.01
32 33
 S
ki
n 
di
se
as
es
 in
 g
en
er
al
 p
ra
ct
ic
e:
 p
re
va
le
nc
e 
an
d 
he
al
th
 c
ar
e 
us
e
C
h
ap
te
r 
2.
1 
3 (0.6%) patients visited only a specialist or alternative health care practitioner, 
respectively. Of the patients who combined several forms of health care, 68 (13.6%) 
visited their GP and a specialist and 14 (2.8%) visited their GP and an alternative 
health care practitioner. In addition, 9 (1.8%) patients visited their GP, a specialist, 
and an alternative health practitioner, and 73 (14.6%) did not contact a health care 
practitioner at all. 
Student’s t-test (see Table 2) comparing the patients who consulted a 
health care practitioner with those who did not showed that patients who visited 
their GP, specialist, or alternative health care practitioner reported a significantly 
higher disease severity, more physical symptoms of itch, and a lower disease-related 
quality of life. 
Discussion
In line with earlier studiese.g.3,4, skin diseases accounted for 12.4% of all diseases 
seen by the participating general practitioners of the CMR. As expected we found 
high prevalence numbers for e.g. psoriasis and atopic dermatitis. Moreover, when 
comparing the results the earlier reported Dutch prevalence numbers of skin 
diseases3,24, these descriptive data indicated a possible increase in the prevalence 
of e.g. atopic dermatitis, seborrheic dermatitis, psoriasis, diseases of the hair, and 
seborrheic keratosis. 
With regard to the use of health care facilities, our results indicated that 
more than 80% of all patients contacted their GP for their skin disease during the 
previous year. Moreover, 65% was only treated by their GP during this year. Patients 
with more severe disease severity, more symptoms of itch, and a low disease-related 
quality of life made the most use of health care services. These findings are in 
line with results for other chronic diseases. For example, Stein et al reported that 
patients with a chronic disease accompanied with severe psychosocial impairments 
made more frequent use of health care facilities23.
 Some limitations of the study should be kept in mind. The use of a 
systematic continuous registration made it possible to gain a unique insight into 
the prevalence of skin diseases and the use of health care facilities by a large group 
of patients with skin diseases. Several subgroups of patients with specific skin 
diseases were relatively small, which made it impossible to draw conclusions for 
specific skin diseases. However, descriptive inspection of the data suggested that 
the results about health care use did not largely differ between groups. Future 
research is clearly needed to study the health care use of specific skin diseases. 
Although the CMR uses generally accepted disease categories for skin disease that 
are compatible with the ICHPPC, the definition of dermatitis as a heterogeneous 
group of skin diseases, which emerge as a reaction to a toxic damage of the skin, 
may have influenced the high prevalence for this category. Finally, it has to be kept 
in mind that (due to the diagnosis-bases character of the CMR registration) several 
variables of e.g. disease duration and the number of visits to the different health 
care providers were assed through self-reported measurements and we cannot 
exclude a possible bias in these measurements.  
 Since patients with a more severe skin disease and a lower quality of 
life made the most frequent use of health care facilities, paying extra attention 
to patients’ physical and psychosocial impairments might have beneficial 
consequences for dermatological treatment, for example by increasing satisfaction 
with treatment and patient compliance with dermatological interventions25,26. 
However, more research is needed to provide insight into the determinants of health 
care use and the effectiveness of current health care facilities in treating specific 
skin diseases. 
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Abstract
Background
Physical symptoms of skin diseases have been shown to negatively affect patients’ 
wellbeing. Although insight in physical symptoms accompanying skin diseases 
is relevant for the management and treatment of skin diseases, the prevalence 
of physical symptoms among patients with skin diseases is a rather unexplored 
territory. 
Objective 
The goal of the present study was to examine the prevalence of physical symptoms 
of itch, pain and fatigue in patients with skin diseases.
 Methods 
On the basis of a systematic morbidity registration system in primary care, 
questionnaires were sent to 826 patients with skin diseases. Eventually, 
questionnaires from 492 patients were suitable for our analyses.
Results
Results indicated that patients with skin diseases particularly experience symptoms 
of itch and fatigue. Approximately 50% of all patients report to experience these 
symptoms and about 25% experience these symptoms as relatively severe. Pain 
was relatively less frequently reported by 23% of all patients, and was on average 
somewhat less intense. The physical symptoms showed relatively strong correlations 
with disease-related quality of life and self-reported disease severity. In contrast, 
only moderate correlations were found with comorbidity and demographic 
variables, which suggests that the physical symptoms of itch, pain and fatigue are 
consequences of the skin diseases.
Conclusion
Itch and fatigue and, to a somewhat lesser extent, pain have a high prevalence 
among patients with skin diseases. Clinicians should be encouraged to carefully 
assess itch, pain and fatigue in patients with skin diseases, and where appropriate 
focus treatment to these symptoms. 
40 41
Pr
ev
el
an
ce
 o
f p
hy
si
ca
l s
ym
pt
om
s 
of
 it
ch
, p
ai
n 
an
d 
fa
ti
gu
e 
in
 p
ti
en
ts
 w
it
h 
sk
in
 d
is
ea
se
s 
in
 g
en
er
al
 p
ra
ct
iv
e
C
h
ap
te
r 
2.
2
Introduction
While it is acknowledged that skin diseases adversely affect quality of life1,2, less 
is known about the prevalence of physical symptoms among patients with skin 
diseases and their relationship with other disease-related variables such as disease 
severity. So far, it is primarily the physical symptom of itch that has been described, 
although pain and fatigue also seem to be present in many patients3-6. Additionally, 
physical symptoms, e.g. itch, have been described to negatively affect quality of 
life5,7. Knowledge of the presence and severity of physical symptoms experienced 
by patients is important for developing guidelines for the management of skin 
diseases. The aim of the present study was to investigate the presence, severity and 
correlates of itch, pain and fatigue in patients diagnosed with skin diseases. 
Methods
Patients and procedures
Patients were recruited from the Continuous Morbidity Registration (CMR) of 
the Department of General Practice of the Radboud University Nijmegen Medical 
Centre, the Netherlands8-10. The CMR consists of four general practices and 11 
general practitioners (GPs). The network was founded in 1971 to study morbidity 
in general practice and records all new episodes of morbidity presented to GPs 
participating in the network. Consequently, the CMR is a diagnosis-based morbidity 
registration in which diagnoses are recorded according to the adapted E-list11, which 
is compatible with the International Classification of Health Problems in Primary 
Care (ICHPPC-2)12. In the Netherlands, the GP is a gatekeeper of access to specialist 
medical care, which enables the CMR to register referrals to medical specialists 
and the specialist-reported diagnoses as well. The CMR network covers a relatively 
stable practice population of approximately 12,000 citizens, which is representative 
in terms of age and sex for the general Dutch population.
For the purpose of the present study, a questionnaire was sent to all 
patients aged 18 years and older who were registered with commonly encountered 
skin disease (see Table 1) during the 12 months preceding the study.  
The questionnaire was administered at a random moment in time and not 
necessarily when the patient visited their GP, a time when the skin disease is 
presumably more active. 
Questionnaires
Physical symptoms of itch, pain and fatigue were assessed on separate Visual Analogue 
Scales (VAS), measuring the mean level of itch, pain and fatigue over the past 4 
weeks4. A VAS score > 2 was considered an indication that patients experienced 
the symptom, and a VAS score > 5 was considered an indication that patients 
experienced the symptom as relatively severe. 
Skin status was assessed with a validated nine-item skin status scale, measuring the 
extent to which different parts of the body are affected4. 
Disease-related quality of life was measured with the Dermatological Life Quality 
Index13. 
Comorbidity was measured with a general checklist of possible comorbidities  
(e.g. diabetes mellitus, cardiac, respiratory or renal insufficiencies).
Duration of the disease was measured as the time since initial diagnoses in years.
Demographic variables were assessed using a general checklist for age, sex, and 
educational level.
Results
Sample characteristics
Of the 826 questionnaires sent to patients, 563 (68.2%) were returned. Due to 
incomplete data sets, data from 492 patients were included in our analyses. The 
mean age of the patients under study was 49.1 years (SD 17.0, range 18.5- 97.6); 
61.2 % of the participants were female, and 6.5%, 60.1% and 33.1% of the patients 
had a primary, secondary and tertiary level of education, respectively. Of all patients 
included in our analyses 40.2% (n = 198) reported having a chronic physical 
condition in addition to their skin disease. Respectively, 136 (27.6%), 48 (9.8%), 
11 (2.2%) and 3 (0.6%) of all patients reported to have one, two, three or four 
other comorbidities besides their skin diseases (e.g. diabetes mellitus, cardiac, 
respiratory or renal insufficiencies). 
Physical symptoms of itch, pain and fatigue
There were 371 patients (73.5%) who reported experiencing at least one of the three 
symptoms (VAS > 2). Itch and fatigue were the most frequently reported symptoms 
(Table 1). These symptoms were reported by more than 50% of the patients (VAS > 
2) and about 25% reported to experience relatively severe itch and / or fatigue (VAS 
> 5). Itch and fatigue were particularly reported by patients with pruritus, psoriasis 
and different forms of eczema. Fatigue was also common among patients with 
skin diseases frequently seen in older patients, such as chronic ulcer and corns. 
In contrast, the mean pain score (M = 1.6, SD = 2.0) was lower than that for itch 
(M = 3.1, SD 2.7) and fatigue (M = 3.1, SD = 2.8). In total, 23.0% of the patients 
experienced pain and 8.9% experienced a relatively severe pain. 
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Table 1. Prevalence of itch, pain and fatigue.
 Itch
Skin disease N M (SD) % patients % patients  
   with itch  with severe
   VAS > 2 itch VAS > 5
Total 492 3.1 (2.7) 53.5 25.8
    
Acne vulgaris  42 1.7 (2.3) 26.2   9.5
Atopic dermatitis 96 3.5 (2.6) 63.5   26.0
Chronic ulcer 5 2.0 (2.1) 40.0   0.0
Contact dermatitis 27 3.8 (2.8) 70.4   29.6
Corns 12 1.3 (1.9) 16.7   8.3
Dermatitis  66 3.3 (2.6) 56.1   31.8
Diseases of hair 6 0.8 (0.8) 0   0.0
Diseases of sebaceous  11 2.9 (2.8) 45.5   36.3
  and sweat glands 
Melanoma 10 1.2 (2.1) 10.0  10.0
Pruritus   7 5.0 (3.5) 95.7   42.9
Psoriasis 112 3.7 (3.0) 60.7   33.9
Seborrheic dermatitis 72 3.0 (2.3) 55.6   22.2
Wart seborrheic 26 2.6 (2.7) 42.3   23.1
 Pain Fatigue
 M (SD) % patients % patients  M (SD) % patients % patients  
  with itch  with severe  with itch   with severe
  VAS > 2 itch VAS > 5  VAS > 2 itch VAS > 5
 1.6 (2.0) 23.0 8.9 3.1 (2.8) 52.4 25.8
     
 1.2 (1.8) 14.3   4.8 3.3 (2.8) 57.1   26.2  
 1.8 (2.0) 26.0   12.5 3.1 (2.6) 52.1   22.9 
 1.2 (0.8) 20.0   0.0 3.8 (2.2) 80.0   20.0 
 1.9 (2.6) 25.9  14.8 3.9 (3.1) 63.0   44.4  
 1.7 (2.0) 33.3 8.3 4.0 (3.6) 58.3   50.0  
 1.5 (1.7) 27.3  6.1 3.1 (2.5) 56.1   25.8  
 1.1 (1.9) 16.7 0.0 3.3 (3.3) 50.0   33.3  
 1.4 (1.6) 27.3 0.0 2.3 (2.5) 45.5  18.2  
 0.7 (0.9) 10.0  0.0 1.6 (2.0) 30.0   0.0  
 2.7 (3.4) 42.9  14.3 2.7 (2.4) 57.1   28.6  
 1.8 (2.4) 25.0  13.4 3.2 (3.0) 51.8   27.7 
 1.2 (1.5) 16.7 2.8 3.0 (2.7) 50.0   20.8  
 1.3 (2.1) 15.4 11.5 2.5 (2.8) 38.5   23.1  
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Correlates of itch, pain and fatigue
Pearson correlation coefficients indicated that itch, pain and fatigue were 
significantly associated with a lower disease-related quality of life and a more severe 
skin disease. In contrast, somewhat lower correlations were found with comorbidity 
and demographic variables. Higher levels of pain and fatigue were also modestly 
associated with more comorbidity (see Table 2). Intercorrelations between itch, pain 
and fatigue revealed moderate correlations between the different symptoms  
(r between 0.38 and 0.49).
Table 2. Correlates of itch, pain and fatigue1.
* p < 0.05,  ** p < 0.01
1 a positive correlation indicates that the physical symptom is related to higher age, female sex, a higher 
educational level, more comorbidity, a longer duration of the skin disease, more disease severity and a reduced 
disease-related quality of life (DLQI).
Discussion
The present study shows that a substantial proportion of patients with skin diseases 
experience physical symptoms, with itch and fatigue being reported by more than 
50% of all patients, 25% experiencing these symptoms as relatively severe. Pain 
was less frequently reported and was, on average, also less intense. Additionally, as 
reported in previous studies (for example, see Yosipovitch14), our findings support 
the notion that the prevalence of itch among patients with psoriasis is comparable 
to that among patients with conditions such as prurigo and different forms of 
dermatitis. 
The moderate intercorrelations between itch, pain and fatigue suggest that 
these symptoms are experienced as different symptoms, although they possibly 
affect and enhance each other. The severity of physical symptoms was relatively 
strongly correlated with disease-related quality of life and self-reported disease 
severity. In contrast, it was only moderately correlated with comorbidity and 
demographic variables, which suggests that the physical symptoms of itch, pain 
and fatigue are consequences of the skin diseases. As expected, itch in particular 
was strongly correlated with disease-related variables. However, the strength 
of the correlations suggests that other determinants could also be important; 
for instance, psychological factors such as cognitive and behavioral reactivity 
to itch have previously been shown to be relevant for this symptom in patients 
with skin diseases15,16. In view of the modest, but significant relationship between 
cormorbidity and the physical symptoms of fatigue and pain, future research should 
further emphasize the specific role of different types and severity of comorbidities 
on patients’ physical well-being.
 In interpreting our findings, it is important to realize that the questionnaire 
was administered at a random moment in time and not when the patient visited 
the GP, the latter being a moment when the skin disease is probably more active. 
This may imply that in general the present study possibly underestimates the 
presence and severity of the physical symptoms. Nevertheless, the present results 
are consistent with the findings of Dalgard et al.6, who also found that itch was 
the dominant skin complaint in the general population. Additionally, we found 
a relatively high prevalence of fatigue and pain in patients with skin diseases in 
general practice.
The present study aimed at a general explorative description of skin 
diseases in general practice. However, several specific groups of skin diseases 
under study had a relatively small sample size, which makes it impossible to draw 
conclusions about each individual skin disease. Furthermore, because of the small 
size of the subgroups of patients with corresponding comorbid diseases we were 
not able to analyse subgroups of specific comorbidities. In addition, a comparison 
between physical symptoms in patients with skin disease in primary care and 
patients seen in secondary care as well as with patients with other chronic diseases 
and the general population is currently lacking. 
Further research is clearly needed for patients with specific skin diseases 
to gain more insight into the determinants of physical symptoms of itch, pain and 
fatigue. However, based on the present findings, clinicians should be encouraged 
to carefully assess itch, pain and fatigue in patients with skin diseases, and where 
appropriate focus treatment to these symptoms. 
  Itch Pain Fatigue 
Demographic variables   
		 	•	Age	 -0.05	 -0.06	 -0.13**
		 	•	Sex	 0.07	 0.09*	 0.17**
		 	•	Educational	level	 -0.14**	 -0.15**	 0.03
Comorbidity 0.06 0.13** 0.22**
Skin-related variables   
		 	•	Duration	of	the	skin	disease	 0.04	 0.04	 0.12*
		 	•	Disease	severity	 0.50**	 0.36**	 0.26**
		 	•		DLQI	 0.55**	 0.46**	 0.38**
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patients with skin diseases in 
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Abstract
Background
Skin diseases are a substantial part of the problems dealt with by general 
practitioners. Although the psychosocial consequences of skin diseases in 
secondary care has been extensively studied, little is known about the psychosocial 
well-being of patients with skin diseases in primary care.
Objective 
To investigate the psychosocial well-being of patients with skin diseases in primary 
care.
Methods 
Questionnaires about the psychosocial consequences of skin diseases were sent 
to patients with a skin disease who were registered within a research network 
(continuous morbidity registration) of general practices that continuously have 
recorded morbidity data since 1971. Questionnaires completed by 532 patients were 
eventually suitable for analyses. 
Results 
Compared with the general population, patients with skin diseases reported 
significantly lower scores for psychosocial well-being. Furthermore, a lower 
psychosocial well-being was significantly related with higher levels of disease-
severity, lower disease-related quality of life, longer disease duration, more 
comorbidity and more physical symptoms of itch, pain and fatigue. After 
demographic variables and comorbidity were controlled for, sequential regression 
analyses showed that disease duration, disease severity and physical symptoms 
(itch, pain and fatigue) were significant predictors of psychosocial well-being.
Conclusion 
The psychosocial well-being of patients with skin diseases in primary care is lower 
than that of the general population. Special attention has to be directed to those 
patients with lowered psychosocial well-being who might be at risk of developing 
severe psychosocial impairments such as clinical depression. 
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Introduction
Increasing attention is being paid to the impact of skin diseases on psychological 
and social well-being. For example, skin diseases such as psoriasis, atopic 
dermatitis or acne have been shown to adversely affect patients’ health-related 
quality of life1-5, also when compared with the general population6-8. This 
impaired well-being has in turn been shown to unfavourably affect the outcome 
of dermatological therapies such as photochemotherapy9, and consequently the 
patients’ skin status. Furthermore, satisfaction and compliance with care are lower 
when quality of life is impaired10,11. In 20-50% of patients with skin diseases in 
secondary care, this impairment may be severe enough to classify the patient at 
risk of severe psychosocial impairments such as clinical depression or psychiatric 
morbidity12-14. Although more severe skin diseases have been associated with a 
poorer quality of life, clinical markers of disease severity and duration are in general 
only modest predictors of psychosocial consequence1-3,15,16. 
Most studies of psychosocial well-being of patients with skin diseases 
have focused on specific dermatological diseases, such as psoriasis and atopic 
dermatitis, and most have been conducted in secondary care. In contrast, little is 
known about the psychosocial consequences of skin diseases in general practice. 
In the Netherlands, a substantial part (at least 10%) of the problems dealt with by 
general practitioners concern skin diseases17-19. These skin diseases are assumed to 
be, on average, less severe than skin diseases seen in secondary care. Given that the 
general practice patient population is likely to differ from the patient population on 
dermatology wards, the psychosocial consequences may also differ. However, the 
psychosocial consequences of skin diseases in primary care have only been studied 
very incidentally20. In addition, the comparison with the general population has 
been made only for specific skin diseases, such as psoriasis21,22. The psychosocial 
functioning of patients with a broad range of skin diseases in primary care has not 
been systemically investigated thus far, and neither has the relationship between 
the psychosocial consequences of skin diseases in primary care and variables such 
as disease severity or duration. 
Studies concerning the well-being of patients with skin diseases have 
usually been conducted at the moment patients present for care, which is when 
patients probably experience increased signs/symptoms. However, it may be more 
representative of patients’ overall well-being to investigate patient’s well-being at a 
random moment in the course of the disease. Consequently, the present study aims 
to examine the psychosocial well-being of patients with skin diseases independent 
of when they went to their general practitioner. For this purpose, questionnaires 
were at a random moment in time administrated to patients who had been 
diagnosed with a variety of skin diseases in general practice. Based on previous 
findings, it was hypothesized that the psychosocial well-being of patients with skin 
diseases in primary care would be lower than that of the general population and that 
the psychosocial consequences would correlate with the severity of the skin disease 
and other skin-related variables. 
Methods
Patients and procedure
Patients were recruited from the four general practices of the continuous morbidity 
registration (CMR) of the Department of General Practice of the Radboud 
University Nijmegen Medical Centre, the Netherlands23,24. This research network 
is based on the Dutch health care system, whereby each citizen is registered 
with a general practitioner, who serves as a gatekeeper for professional medical 
care. Consequently, the general practice has an overview of their patients’ full 
medical history, including diagnoses made after referral to specialists. The CMR 
network was founded in 1971 to study morbidity in general practice and records 
all new episodes of morbidity presented to the general practitioner. Diagnoses are 
classified and coded by the general practitioners, using the Dutch translation of 
the adapted E-list25,26, the standard available in 1971. Later revisions have made this 
list compatible with the International Classification of Health Problems in Primary 
Care (ICHPPC-2)27. The resulting dataset makes it possible to track the medical 
life history of individuals over more than 30 years. The total practice population 
has remained stable at approximately 12 000 citizens over the years28-30. To ensure 
reliable and consistent recording and classification over time, a number of quality 
assurances have been developed in addition to the use of a standardized disease 
classification. For example, all general practitioners in the network meet regularly 
to discuss and compare their registration and classification work. If there are 
problems with the registration, consensus is sought and registration rules are 
revised. Furthermore, new general practitioners who join the practices are trained 
in the use of the classification and the registration rules. The sociodemographic and 
family characteristics of patients are entered in the registration system by practice 
assistants, who also monitor the completeness of the records after surgeries. 
Practice assistants are trained and supervised for these purposes. These quality 
assurances have resulted in highly reliable data for a variety of health problems31. 
All patients of the participating general practitioners are informed about the 
use of the database for research and asked to sign for their consent. If patients 
leave a practice, their new address and the name and address of the new general 
practitioner are recorded to enable future contacting.
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For the purpose of the present study, questionnaires were sent to patients 
aged 18 years or older with one of the following diagnostic categories of common 
skin diseases, which were diagnosed and recorded during the 12 months preceding 
the study: acne vulgaris, atopic dermatitis, contact dermatitis, corns, chronic 
ulcer, dermatitis, diseases of sebaceous glands and sweat glands, diseases of the 
nail, diseases of hair, psoriasis, pruritus, seborrheic dermatitis, seborrheic wart, 
sebaceous cyst, melanoma, squamous cell carcinoma, benign neoplasm of the skin, 
and other skin carcinomas (diagnostic terminology according E-list25,26). 
Self-reported measures
Demographic variables were assessed using a general checklist for age, gender and 
education. The latter was measured using seven categories that can be classified as 
primary, secondary and tertiary levels of education, representing on average 7, 12, 
and 17 years of formal education.
Skin status was assessed with a nine-item skin status scale, measuring the degree to 
which different parts of the body (face, haired head, neck, hands, arms, torso, legs, 
feet and genitals/ anus) were affected by the disease, with response categories on a 
four-point Likert scale ranging from “not” (1) to “totally” (4)32,33. A total score for the 
affected area of the body was calculated by adding up the scores of the nine items. 
Physical symptoms of itch, pain and fatigue were assessed on a Visual Analogue Scale 
(VAS), measuring the mean level of itch, pain and fatigue over the past 4 weeks  
(0 = no itch/pain/fatigue; 10 = worst itch/pain/fatigue ever experienced). 
Psychological and social well-being were measured with the subscales Social 
Functioning and Mental Health of the Dutch version of the SF-36 questionnaire34,35. 
The Social Functioning scale asks about restrictions in social activities due to health 
problems. The Mental Health scale was used to measure psychological well-being. 
This scale asks about feelings of depressiveness and nervousness and can also be 
used to identify patients at risk of clinical depression36. Lower scores on both scales 
indicate a lower well-being.
Comorbidity was measured as the presence of chronic physical conditions other than
the skin disease. 
Disease duration was measured as the time since initial diagnosis in years.
Statistical analyses
Data were analysed using the SPSS program (version 12.0). Differences in 
demographic variables between responders and non-responders were tested with 
Student’s t-tests. Differences in mean scores for psychological and social well-being 
between patients with skin diseases in primary care and age- and gender-matched 
norm groups of the general Dutch population35 were tested by means of Student’s 
t-tests. The cut-off scores for psychological well-being as described by Ware et al.36 
were used to calculate the percentage of patients at risk of a diagnosis of clinical 
depression. In addition, Pearson’s and point biserial correlation coefficients were 
calculated between psychosocial functioning and variables of disease severity, 
physical symptoms (itch, pain and fatigue), disease duration, comorbidity, 
disease-related quality of life and demographic variables (age, gender and level of 
education). Finally, sequential regression analyses were performed to analyse the 
relative contribution of disease characteristics of severity and duration and physical 
symptoms of itch, pain and fatigue to psychosocial well-being, after controlling 
for demographic variables and comorbidity. Demographic variables (age, gender, 
educational level) were entered in the first step, followed by comorbidity in the 
second step. In the third step disease duration was entered, followed by disease 
severity in the fourth step. In the final and fifth step physical symptoms of itch, pain 
and fatigue were entered. 
Results
Sample characteristics
Of the 857 questionnaires sent, 583 (68.0%) were returned. Due to missing values, 
only the questionnaires of 532 patients were suitable for analysis. The mean age 
of the respondents was 49.9 years (SD 17.2, range 18.5 - 97.6) and 61.3% of all 
participants were female. Respectively, 7.8%, 57.4% and 34.8% of the patients 
had a primary, secondary and tertiary level of education. The mean duration of 
skin disease was 16.9 years (SD 15.5, range 0.1-67.1). There were no significant 
demographic differences between the responders and non-responders with regard 
to gender and educational level. However, patients who returned the questionnaire 
were significantly younger (t = 3.9; p < 0.01) than the patients who did not. Of 
all patients included in our analyses 40.2% reported to have a chronic physical 
condition in addition to their skin disease. Respectively, 144 (28.1%),  
49 (9.6%), 10 (1.9%), and 3 (0.6%) of all patients reported to have one, two, three 
or four other comorbidities besides their skin diseases (e.g. diabetes mellitus, 
cardiac, respiratory or renal insufficiencies). Of patients with diseases of the nail, 
sebaceous cyst, squamous cell carcinoma, benign neoplasm of the skin and other 
skin carcinoma, fewer than five patients returned the questionnaire, so we were not 
able to determine the influence of these skin diseases on the outcome measures 
of psychological and social well-being. The following completed questionnaires 
were available for the other skin diseases under study: acne vulgaris (n = 41), atopic 
dermatitis (n = 101), chronic ulcer (n = 6), contact dermatitis (n = 28), corns  
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(n = 11), dermatitis (n = 70), diseases of the hair (n = 6), diseases of sebaceous 
glands and sweat glands (n = 12), melanoma (n = 12), pruritus (n = 7), psoriasis  
(n = 117), seborrheic dermatitis (n = 73) and seborrheic wart (n = 29). 
Level of psychosocial well-being 
Mean scores for psychological and social well-being are shown in Table 1. When 
compared with the general Dutch population, patients with skin diseases in primary 
care reported a significantly lower psychological (t = 3.3, p < 0.01) and social  
(t = 3.3, p < 0.01) well-being. Further introspection of data indicated that patients 
with each of the skin diseases separately reported a lower psychosocial well-being 
than the general population. This was true for each individual skin disease, except 
for patients with diseases of sebaceous- and sweat glands regarding psychological 
well-being, and patients with melanoma and seborrheic wart regarding social well-
being. In total 14.5% of all patients had a score ≤ 52 on the scale for psychological 
well-being, indicating a potential risk of developing severe psychological 
impairment such as clinical depression. 
Table 1. Mean scores (M) and standard deviations (SD) for psychosocial well-being of patients with 
skin diseases.
Correlates of psychosocial consequences
Correlation coefficients for psychosocial well-being and other study variables for 
all skin diseases are presented in Table 2. Lower scores for psychological and social 
well-being were modestly, but significantly, associated with male gender, lower 
educational level and more comorbidity. Small to moderate significant correlations 
were found between lower psychosocial well-being and more severe disease, longer 
disease duration, and more physical symptoms of itch, pain and fatigue. 
 Sequential regression analyses (data not shown) further indicated that, 
after controlling for demographic variables of age, gender and educational level 
 (R2 0.03, p < 0.01, Fchange 4.26) and the presence of comorbidities (R2 0.01,  
p < 0.05, Fchange 6.73), disease duration (R2 0.01, NS, Fchange 2.74) and disease 
severity (R2 0.03, p < 0.01, Fchange 12.43) significantly predicted psychological  
well-being. In addition, physical symptoms of itch, pain and fatigue had an 
additional significant predictive value (R2 0.17, p < 0.01, Fchange 33.46). The same 
pattern was found in the sequential regression analyses predicting social well-
being. After controlling for demographic variables in the first step (R2 0.03,  
p < 0.01, Fchange 4.31) and the presence of comorbidities in the second step  
(R2 0.05, p < 0.01, Fchange 22.00), disease duration (R2 0.02, p < 0.01, Fchange 
9.20) and severity (R2 0.03, p < 0.01, Fchange 15.20) in the third and fourth step and 
physical symptoms in the final step (R2 0.19, p < 0.01 Fchange 40.63) were found 
to be significant predictors of social well-being. The total R2 values for the models 
predicting psychological and social well-being were 0.49 and 0.56, respectively.
  Psychological well-being Social well-being
  M SD M SD
Total 71.6 17.2 79.8 22.3
    
Acne vulgaris 69.8 16.8 78.6 24.2
Atopic dermatitis 74.6 16.9 80.2 22.5
Chronic ulcer 71.3 21.8 60.4 37.4
Corns 65.1 20.9 75.0 23.0
Contact dermatitis 67.7 17.2 77.7 19.1
Dermatitis 72.1 18.7 81.3 21.6
Diseases of hair 62.0 8.3 62.5 13.7
Diseases of sebaceous and sweet glands 79.3 18.7 80.2 20.3
Melanoma 76.3 9.6 91.7 15.4
Psoriasis 70.3 18.4 79.1 24.6
Pruritus 64.6 16.6 71.4 30.4
Seborrheic dermatitis 70.7 16.5 80.1 20.5
Seborrheic wart 75.2 14.7 87.1 17.5
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Table 2. Correlates of psychosocial well-being1 
* p < 0.05, ** p < 0.01
1   a negative correlation indicates that a lower well-being is related to higher age, female gender, a higher 
educational level, the presence of comorbidity, a longer duration of the skin disease, more disease severity 
and more severe symptoms of itch, pain and fatigue.
Discussion
The present study investigated the psychosocial well-being of patients with skin 
diseases in primary care in comparison with the general population. Results of 
the study showed that patients with skin diseases in primary care have a lower 
psychosocial well-being than the general population and that a considerable 
number of these patients are at risk of developing severe psychological impairment 
such as clinical depression. The psychosocial impairments were greatest in patients 
with more severe and longer-lasting skin disease, more physical symptoms and 
other chronic morbidities. 
Generally, these results are in line with findings from secondary care, 
where patients with skin diseases have a relatively lower well-being than the 
general population6-8. As could be expected, the percentage of patients at risk for 
psychosocial impairments such as a clinical depression was somewhat lower in this 
primary care study than in secondary care12-14 but still concerned a large number of 
patients. This finding may indicate that the impact of skin diseases on psychosocial 
well-being is less substantial in primary care than in patients referred to secondary 
care. However, the present study determined patients’ well-being independent of 
when the patients sought care whereas in other studies information was recorded 
when patients consulted a general practitioner or a dermatologist, a moment 
when the skin disease is presumably more active. This may explain the somewhat 
lower scores for patients at risk of severe psychological impairment such as clinical 
depression. Nevertheless, the results of the present study show that clinicians 
should be aware of the possibility that skin diseases may severely diminish the well-
being of patients and may even cause psychosocial impairments such as a clinical 
depression. In addition to secondary care, the general practice seems suitable 
for early screening for this risk profile by use of validated screening instruments, 
followed by multidisciplinary treatment for those patients at risk. 
The impact that their skin diseases had on patients’ psychosocial well-
being was similar to that found for other chronic diseases in primary care, for 
example migraine34 or multiple sclerosis37. This suggests that there may be generic 
psychological patterns among patients with various chronic conditions, and 
that common physical, psychological and social factors may contribute to the 
psychological well-being of patients with different types of chronic diseases32,42. The 
correlates between psychosocial well-being and disease severity, physical symptoms 
and comorbidity suggests that future research should specifically pay attention 
to chronic skin diseases that frequently cause (chronic) physical symptoms of 
itch, pain and fatigue and which are accompanied by other comorbid, chronic 
diseases. In view of the modest, but significant relationship between the presence 
of cormorbidity and the psychosocial well-being of patients, future research should 
emphasize the specific role of different types and severity of comorbidities on 
patients’ well-being.
In addition, the modest contribution of disease severity to psychosocial 
well-being is consistent with findings of previous (secondary care) studies2,38-41, 
and supports the notion that the skin disease itself contributes to psychosocial 
impairments, although other (non-disease-related) factors may contribute as well. 
Stigmatisation experience, coping strategies, social support and personality factors 
have been recognised contributors to the well-being of patients with skin diseases 
and should be taken into account in future studies2,38-40-42-43. 
Some limitations of the study have to be mentioned. The present study 
aimed at a general description of skin diseases in general practice. The SF-36, a 
generic questionnaire suitable for different study populations, was chosen to make 
a comparison between the general population and patients with skin diseases 
possible. The SF-36 is internationally frequently used and there are several (inter)
national norms available. However, some skin diseases under study had a relatively 
small sample size, which made it impossible to draw conclusions about the impact 
  Psychological well-being Social well-being
Demographic variables  
		 	•	Age	 -0.07	 0.02
		 	•	Gender	 -0.12**	 -0.15**
		 	•	Education	 0.15**	 0.10*
Comorbidity -0.12** -0.22**
Skin-related variables  
		 	•	Duration	of	the	skin	disease	 -0.08	 -0.16**
		 	•	Disease	severity	 -0.15**	 -0.18**
		 	•		Physical	symptoms 
- Itch -0.28** -0.27** 
- Pain -0.26** -0.30** 
- Fatigue -0.45** -0.53**
60 61
C
h
ap
te
r 
2.
3
Ps
yc
ho
so
ci
al
 w
el
l-b
ei
ng
 o
f p
at
ie
nt
s 
w
it
h 
sk
in
 d
is
ea
se
s 
in
 g
en
er
al
 p
ra
ct
ic
e
of each individual skin diseases on well-being. Furthermore, despite the fact 
that the CMR is representative for the general Dutch population with regard to 
demographic characteristics, the study population may not be truly representative 
of the general population due to the slight differences in age between responders 
and non-responders. Future studies should consequently pay particular attention to 
older patients with skin diseases in primary care. It also has to be kept in mind that 
the relatively small scales for psychological and social well-being cannot describe 
the entire domain of psychosocial well-being. However, the two scales have been 
shown to have a good reliability and validity for measuring psychological and social 
well-being in the general population as well as in patients with chronic physical 
diseases34-36. In addition, although the use of generic questionnaires enabled us 
to compare the general practice population with the general population, it may 
hamper comparison with studies that used questionnaires designed for specific 
dermatological conditions. A systematic comparison between skin diseases in 
primary and in secondary care with regard to disease-specific aspects warrants 
future research. Moreover, self-report questionnaires may be unsufficient for 
the complete information relevant to the identification of patients at risk of 
being diagnosed with clinical depression. Although, the validity of self-reported 
instruments for identifying patients at risk has widely been validated14,44, the need 
for a clinical interview, to examine patients’ clinical psychiatric state, in addition to 
questionnaires should be emphasized.
In conclusion, the results of the present study indicate that the psychosocial 
well-being of patients with skin diseases in primary care is on average lower than 
that of the general population and that several disease characteristics influence 
this well-being. Special attention should be paid to a subgroup of patients with 
skin disease in primary care that may be at risk of more severe psychosocial 
impairments, such as clinical depression. The general practice setting seems to be 
suitable for early detecting and treatment of this risk profile.
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Abstract
Background
Itch is a major feature of many skin diseases, which adversely affects patients’ 
quality of life. Beside disease severity, psychophysiological factors have been 
proposed to influence the itch sensation. 
Objective
In this review the evidence for a biopsychosocial model of itch is described, focusing 
in particular on evidence for the effects of personality characteristics, external 
stressors, cognitive, behavioral and social factors, and the possible mediating role 
of physiological processes. 
Methods
Scientific literature was searched within electronic databases by means of key words 
based on stress-vulnerability models. In addition, reference sections of articles were 
screened manually. Only international published studies on itch in skin diseases 
were included in this review. 
Results
Research so far indicates that stressors may have a role in the itch sensation of 
patients with skin diseases. Furthermore, cognitive factors such as helplessness and 
worrying, and the behavioral response of scratching have been indicated as possible 
worsening factors. 
Conclusions
Overall, findings are in favor of a biopsychosocial model for the itch sensation. 
However, there is a strong need for more, methodologically sound research in order 
to fully understand the processes underlying the itch sensation. 
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Introduction
Itch is a major symptom of many chronic skin conditions and affects a considerable 
number of patients with, for example, atopic dermatitis, contact dermatitis, 
urticaria and psoriasis1,2. Itch has been defined as a sensation that provokes the 
desire to scratch3. Moreover, itch has been shown to lower patients’ quality of life4–6, 
which in turn unfavorably affects the outcome of dermatological therapies, such 
as photochemotherapy7 and, consequently, the patients’ skin status1,4,8. Disease 
severity alone usually cannot fully account for the intensity of itch and, although 
several treatments are available, none is generally effective9. Due to the overall 
modest relationship between itch intensity and severity of the skin diseases of, 
for example, psoriasis and atopic dermatitis4,8,10,11, other factors have also been 
proposed to influence itch intensity. In addition to factors such as sweating, skin 
dryness, or physical effort, psychological factors have regularly been described to 
influence the itch intensity4,8,12. One of the most striking examples of the influence 
of psychological factors on itch came from the observation that itch (and the 
scratching response) could be aggravated by showing individuals itch-related 
pictures of fleas, mites, scratch marks, allergic reactions, etc.13. Furthermore, it has 
been described that psychological comorbidity (e.g. clinical depression) is high 
among patients suffering from itch14–16 and that negative emotions can increase the 
level of itch17. 
In contrast to the traditional biomedical model (which focuses merely 
on the physical processes of a disease and does not take into account the role of 
psychosocial factors), the observation that disease severity alone usually cannot 
fully account for the intensity of itch, as well as the influence of psychological 
processes in the itch sensation, support a biopsychosocial model of itch in patients 
with chronic skin diseases. Biopsychosocial factors can best be shown in a diathesis-
stress model, which is based on the hypothesis that internal vulnerability factors 
(diathesis), such as personality, interact with external environmental factors (such 
as major life events and other stressors) to trigger a disease or itch (Fig. 1). In this 
model, cognitive, behavioral and social factors, such as illness cognitions, coping, 
or perceived social support can be considered as mediating or moderating factors 
that can enhance the disease and symptoms of itch. It is assumed that these factors, 
at least partly, account for the effects of stressors and personality characteristics on 
disease. For example, the influence of a stressful event on disease severity and itch 
may be explained by how patients cope with the stressful event. Another well-known 
example is the effect of social support on the relationship between stressors and 
disease severity: stressors might unfavorably affect disease severity and itch only in 
the event of low levels of social support. 
Specifically for itch, scratching is an important mediating factor in this 
model. Scratching in response to itch is an unconscious and autonomic response, 
as reflected by the definition of itch as an unpleasant sensation, which evokes the 
desire to scratch17. However, due to a vicious itch-scratch-itch cycle, scratching 
may become a problem in its own right. These factors may, in turn, be affected 
by psychological factors of sensory information processing18. For example, it has 
been reported that patients with chronic itch conditions have a lower threshold for 
sensory stimuli in general and for itch specifically19–21. This might be due to changes 
in information processing such as an attentional- or interpretational bias to general 
or itch specific stimuli, or catastrophizing expectations about aversive stimuli19,22.
Several physiological processes can also mediate the relationship between 
itch and psychological factors (see Fig. 1). It is nowadays well-known that, for 
example, specific cutaneous sensory C-nerve fibers serve as pruriceptors23-
25, transmitting sensory stimuli from the skin through the dorsal horn to the 
spinothalamic tract. Several internal mediators, e.g. histamine, serotonin, 
prostaglandins, and cytokines, can bind to the nerve endings of these itch receptors 
and induce axonal firing26-29. Considering the possible influence of stressors on itch 
in patients with skin diseases, external stressors can activate the stress response 
system in the brain (hypothalamic-pituitary-adrenal axis; HPA axis), and the 
hormones of this HPA axis in turn activate mast cells in the skin30,31. In addition, 
external stressors can induce autonomous responses, such as transpiration, which 
can also worsen itch sensations4,12. 
Fig. 1. Biopsychosocial model of itch
Internal factors:
	 •	Personality	
Mediating factors:
 Cognitive factors e.g.
	 	 •	Helplessness
	 	 •	Worrying
 Behavioral factors.
	 	 •	Scratching
	 	 •	Avoidance	behavior
 Social factors
	 	 •	Perceived	support
	 	 •	Social	network
Physiological 
factors
Itch
External factors:
	 •	Stressors
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Purpose and methods of this study
While research so far has focused on the individual components of the 
biopsychosocial model of itch, the whole model has not yet been systematically 
described, particularly with regard to the evidence for psychological factors. 
Therefore, the aim of the current review is to summarize evidence for the 
biopsychosocial model of itch, in particular the evidence for possible pathways for 
the influence of psychological factors on itch. Although different forms of itch have 
been classified and the neurophysiology of itch greatly depends on the type of itch32, 
in this review we will focus on chronic itch related to skin diseases. For this purpose, 
we will describe data about the relationship between itch and internal factors of 
relatively stable personality characteristics (a relatively stable pattern of individual 
thoughts, emotions and actions), external stressors, as well as the influence of 
cognitive, behavioral and social factors on itch in patients with skin diseases.
The electronic databases used in our search for relevant studies included 
MEDLINE (1970-2007), PSYCHINFO (1970-2007), EMBASE (1980-2007), and 
Cochrane library (1993-2007). Based on diathesis-stress models, the keywords 
“itch”, “itching” and “pruritus” were used in combination with “psychological”, 
“psychiatric”, “stress”, “stressors”, “life events”, “hassles”, “personality”, “mood”, 
“affect”, “emotion”, “tension”, “anxiety”, “depression”, “neuroticism”, “scratch”, 
“coping”, “cognitions”, “helplessness”, “avoidance”, “acceptance”, “worrying”, 
“catastrophizing”, “stigmatization”, “efficacy”, “perceived control”, “behavior”, 
“social” and “support”. In addition, reference sections were screened manually. 
Only international published studies on itch in skin diseases were included in this 
review. 
Personality characteristics and itch
It has been suggested that certain personality traits are associated with the 
development or exacerbations of skin disorders33–36. In particular, for patients with 
chronic inflammatory diseases, such as atopic dermatitis and psoriasis, a specific 
personality profile (with a relatively stable experience of negative emotional states) 
has been suggested33,36–40. However, research has generally failed to show that 
patients with skin diseases have such a distinct personality profile. Nevertheless, 
several emotional features (such as anxiety or depression) have frequently 
been found to be elevated in patients with chronic skin diseases, probably as a 
consequence of the skin disease rather than as a contributory cause of the skin 
condition34,35,39,41–46.
There is evidence for an association between negative affectivity (e.g. 
depression and anxiety) and the outcome of itch and the related scratching 
response. For example, preliminary results indicate that the level of anxiety 
is correlated with the intensity of itch in patients with chronic skin diseases47. 
Furthermore, elevated levels of anxiety are associated with increased conditioning 
of a scratch response in patients with atopic dermatitis48. For depression, findings 
suggest that a depressed clinical state may influence the itch intensity49–51. For 
example, the level of itch before and after standard dermatological treatment (of, 
for example, topical steroids or ultraviolet-B light) in patients with psoriasis was 
significantly associated with changes in depression before and after treatment50. In 
addition, negative affectivity in terms of neuroticism has also been associated with 
itch intensity in patients with psoriasis as well as atopic dermatitis8, while other 
studies have failed to find a relationship between itch and negative affectivity44,46. 
Gupta reported a correlation between a tendency to experience dissociative states (a 
state where the person withdraws from the body or reality, occurring mostly during 
or after psychological trauma) and itch in a non-clinical population52.
These findings regarding personality and itch severity should be interpreted 
with caution. Although in some cross-sectional studies a statistically significant 
correlation was found, the direction of causality remains unclear. It is reasonable 
that some of these previous described symptoms, for example anxiety, depression, 
and experiencing dissociative states, are a consequence, rather than a cause, of 
having a chronic dermatological disorder accompanied by chronic itch. Dissociative 
states could, for example, be a functional way of coping with chronic itch, while it 
may be a way to withdraw from the unpleasant itch experience. In addition, there 
may be an indirect relationship between negative affect and itch. For example, in 
other chronic diseases, patients with more negative affectivity are known to be more 
vulnerable for dysfunctional coping styles when affected by disease (e.g. a passive-
avoidant coping style), which in turn have been shown to be risk factors for a worse 
disease outcome53,54.
Stressors and itch
Many patients (37–88%) with chronic skin diseases believe that there is a 
relationship between external stressors and their skin disease55–59, and this 
relationship has received increasing attention over the years43,58–68. Although 
research on this subject is often methodologically flawed (e.g. small sample size, 
limited number of repeated measurements), results suggest that stress factors are 
associated with disease severity in patients with skin diseases. For example one 
of the few prospective studies by King & Wilson69, indicates that in patients with 
atopic dermatitis, self-reported stressors are predictors of disease severity one day 
later. The influence of stressors on the physical symptom of itch has received far 
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less attention. While to our knowledge there have been no prospective studies on 
this subject, some experimental and cross-sectional studies indicate that stress 
factors can influence itch. For example, an early experimental study by Edwards 
et al. indicated that perceived stress affected the capability of healthy subjects to 
discriminate among itch stimuli70.
A frequently used distinction between stressors is the division into major life 
events (e.g. divorce, loss of a loved one) and minor life events (daily hassles of, for 
example, interpersonal conflicts or running late for an important meeting). Major 
and minor life events have been shown to be associated with higher levels of itch 
in the general population and in patients with skin diseases50,71,72. Moreover, one 
study showed that experimentally evoked stress heightened itch in patients with 
skin diseases73. Additionally, perceived stress due to major or minor life events has 
been found to be associated with the presence (and severity) of itch in patients 
with psoriasis in some studies74,75 but not in others50. In skin diseases, the feeling 
of being stigmatized (e.g. the experience that others stare, feel uncomfortable 
touching patients, make annoying comments, or avoid contact at all) also 
reflects the individual’s perceived stress. Stigmatization has been shown to be 
related to higher levels of itch in patients with atopic dermatitis and psoriasis47,76. 
Furthermore, high stress reactors, that is patients who indicate that their disease 
severity is strongly associated with stress, reported significantly more itch and a 
stronger itch/scratch cycle than low stress reactors77,78, which suggests that stressors 
may have different effects on the symptom of itch in different subgroups of patients. 
Overall, studies of the relationship between stress factors and itch indicate 
that the subjective experience of stressors might be associated with increased 
itch in patients with skin diseases. However, further prospective and experimental 
research is necessary to fully comprehend the relationship between different types 
of stressors (life events as well as perceived stress) and itch in different types of skin 
diseases.
Mediating factors
As shown in Fig. 1, specific cognitive, behavioral and social factors are assumed to 
mediate a persons’ skin reactivity and response to itch. 
Cognitive factors
Individual differences in the long-term adjustment to chronic diseases may be 
explained by different ways of cognitive evaluation (illness cognitions) of the 
aversive nature of the chronic condition and its symptom45,53. Although there are 
several conceptualizations of illness cognitions, two main constructs might be 
particularly relevant for itchy skin diseases as well as other chronic diseases: (i) 
cognitions that emphasize the negative meaning (e.g. helplessness or worrying); 
and (ii) cognitions that diminish the aversive meaning of the condition (e.g. 
acceptance)53.
Helplessness. Since most chronic diseases are still incurable and the course of the 
disease is often unpredictable, patients may experience helplessness because of 
this lack of control over their disease. Helplessness is reflected by the tendency 
to emphasize the negative aspects of the disease as being uncontrollable, 
unpredictable and unchangeable, and to generalize these feelings to all aspects of 
life53. In line with other chronic conditions in which helplessness has been shown to 
influence physical symptoms53, preliminary results indicate that helplessness may 
be associated with higher levels of itch in skin diseases10. Additionally, helplessness 
has been related to a lower psychological well-being10 and appeared to be the 
strongest predictor of perceived stress, such as feelings of stigmatization, in 
patients with skin diseases76. 
Worrying. Related to the concept of helplessness is the cognitive status of 
perseverating worrying. About 40% of patients with a chronic skin condition show 
general pathological worrying22,79, and disease-specific worrying has been shown 
to be associated with more severe disease severity in patients with skin diseases8,80. 
Furthermore, Fortune et al. reported that general worrying predicted the effect of 
UVB light therapy in patients with psoriasis7. Patients with high levels of worrying 
needed more radiation treatments to clear their psoriasis. 
Acceptance. In contrast to helplessness and worrying, which focus on the negative 
meaning of the disease and seem negatively to influence the disease course, 
acceptance may have beneficial effects on skin diseases. Cognitions of acceptance 
are to acknowledge the fact of being chronically ill and simultaneously perceiving 
the ability to live with, and master the consequences of, the disease53. Some studies 
have found a relationship between acceptance and physical well-being in patients 
with skin diseases10, while others have not81. Acceptance has also been shown to be 
correlated with less itch intensity10. Since higher levels of psychological distress have 
been related to higher levels of helplessness and less acceptance10, it is possible that 
these psychological cognitions mediate the distress caused by itch in patients with 
skin diseases.
Behavioral factors
For skin diseases in general, behavioral coping strategies are directly associated 
with disease-related outcomes in patients with chronic skin diseases82,83, specifically 
scratching. The subjective sensation of itch is strongly correlated with the scratching 
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response (measured by behavioral indicators as well as questionnaires)47,84. The 
sensation of itch induces a universal cascade in humans and animals to scratch. 
The positive effect of scratching could be the removal of the causal agent, such 
as parasites or plant particles. The immediate reinforcement of scratching is 
the reduction of itch; however, patients with enduring itch due to chronic skin 
diseases persist in their scratching behavior (even until the skin bleeds) and this 
perceived loss of control may lead to negative emotional feelings. In addition, 
scratching can be sustained by long-term reinforcement (for example, through 
attention from other people). Consequently, in the long-term scratching may 
develop into a conditioned response to stressors and other stimuli beside itch, 
which may be particularly relevant in patients with chronic itch. As mentioned 
earlier, scratching induces several physiological responses. For example, it has been 
shown that repeated scratching decreases prostaglandin D2 (PGD2) levels - an 
itch inhibitor - in the skin, resulting in an increased desire to scratch and inducing 
the itch-scratch cycle85,86. Furthermore, functional positron emission tomography 
(fPET) and functional magnetic resonance imaging (fMRI) studies have recently 
showed that itch is related to brain regions implicated in motivational processes 
(e.g. orbitofrontal cortex, striatal region, subgenual anterieur cingulated cortex), 
which could reflect the desire to relieve the itch probably through scratching87,88. 
Furthermore, animal studies have shown that scratching may induce skin conditions 
by influencing various immunological responses: less scratching behavior has been 
shown to result in altered levels of several interleukins (IL-5, IL-13, IL-18, interferon-
γ)89. Although scratching induces relief of symptoms in the short term, scratching 
often becomes a principal problem in its own right in the long term, due to a vicious 
circle of itching, scratching, and scratching wounds that in turn cause itch. Through 
this vicious cycle of itch-scratch-itch, scratching may have an important role in the 
maintenance and exacerbation of chronic skin disorders. In turn, the itch-scratch 
cycle has been found to correlate with higher levels of worrying and helplessness, 
less acceptance, and anxious-depressive mood47,80,90, suggesting that certain 
psychological factors (such as illness cognitions, behavioral factors, and external 
stressors) may influence the itch-scratch cycle. 
In addition to scratching, other coping behaviors may influence the itch 
sensation of patients with chronic skin disease in the long-term. In particular, 
enduring patterns of avoidant coping behavior in response to itch attacks (e.g. 
quitting activities or retreating to a restful environment when experiencing itch) has 
been shown to be related to higher levels of itch, more scratching, and higher levels 
of disease-related disability8,58. This is consistent with findings for other chronic 
conditions where avoidance behavior towards the disease has also been described 
negatively to influence the disease outcome. For example, in patients suffering from 
chronic pain it is well known that passive-avoidance behavior negatively influences 
long-term disease outcomes91–93. In contrast to acute pain, acute itch is a trigger for 
increased activity patterns (scratching). However, chronic itching usually causes 
patients to withdraw from activities or to avoid daily activities, which may lead 
to a reduced quality of life in the long term. Avoidance behavior has indeed been 
shown to be related to disease-related quality of life in patients with chronic skin 
conditions that are frequently accompanied by itch82,83.
Social factors
Social support can be broadly defined as interactions or resources provided by 
others that may help an individual cope with stress94. The influence of social 
support on general physical and psychological health outcomes has frequently 
been described95–98. There is also relatively strong evidence that higher levels of 
social support are associated with better cardiovascular regulation (e.g. lower blood 
pressure) and immune functioning. The relationship between social support and 
endocrine functioning is somewhat less clear. Although such relationships have 
repeatedly been reported, the underlying mechanisms are relatively unclear. For 
example, increasing solely social contact levels did not affect key parameters of 
neuroendocrine function, such as cortisol levels95.
The influence of social support on itch requires more attention, while only 
a few studies address this subject. Preliminary results indicate that social support 
(perceived support and size of social network) is not associated with itching10,72. 
However, social support may have a protective effect when individuals are exposed 
to possible disease-triggering events96. Picardi et al.99 investigated the role of 
social support in outpatients with recent-onset psoriasis or with exacerbation of 
their disease. Preliminary results indicate that subgroups of patients differ in their 
perceived level of social support66. Social support may also have a mediating role in 
the relationship between itch and distress, since lower levels of social support are 
reported to be associated with higher levels of distress10.
Conclusions
The aim of this review was to provide an overview of the evidence for a 
biopsychosocial model of itch in patients with chronic skin diseases. In particular, 
evidence for a relationship between internal factors of relatively stable personality 
traits, external stressors, and the influence of possible mediators (cognitive, 
behavioral and social factors) on itch was summarized. Considering that disease 
severity alone cannot fully account for the itch sensation and the preliminary 
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empirical support for a relationship between the biopsychosocial pathways and itch, 
the theoretical model seems to have an additional value in gaining insight into the 
complex determinants of itch and its treatment in skin diseases. Overall, findings 
support the biopsychosocial model of itch. However, further research is needed 
before the underlying mechanisms can be fully understood. While most research 
into psychological factors and the itch sensation is based on cross-sectional studies, 
there is a strong need for studies with a methodologically sound design (e.g. studies 
with an experimental or prospective design). 
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Chapter 3.2 -  Cognitive, behavioral, and 
physiological reactivity to chronic 
itch: analogies to chronic pain
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Abstract 
Background
It is well-known that cognitive, behavioral, and physiological reactivity to pain, 
such as worrying, avoidance of activity and increased physiological responses, 
can unfavorably affect long-term outcomes in patients with chronic pain. In line 
with similarities between the psychophysiology of pain and itch, corresponding 
mechanisms may be relevant for the maintenance of chronic itch. 
Objective
The goal of this study was to examine the role of self-reported cognitive, behavioral 
and physiological reactivity factors on itch-related outcomes in patients with chronic 
skin diseases suffering from chronic itch.
Methods
Questionnaires about itch, scratching and disease-related quality of life were sent 
to 269 patients with atopic dermatitis and psoriasis seen at our dermatological 
ward. Moreover, the questionnaire gained information about worrying, avoidance 
behavior and physiological reactivity. Eventually, questionnaires from 235 patients 
were suitable for our analyses.
Results
Sequential regression analyses indicated that all three reactivity systems predicted 
itch-related outcomes. Specifically, more worrying, higher levels of avoidance of 
activity and heightened self-reported physiological reactivity predicted more itch, 
more scratching, and a reduced disease-related quality of life. 
Conclusions
The results suggest that a psychological model as described for chronic pain is a 
useful starting point for study of the maintaining mechanisms of chronic itch. 
90 91
C
og
ni
ti
ve
, b
eh
av
io
ra
l, 
an
d 
ph
ys
io
lo
gi
ca
l r
ea
ct
iv
it
y 
to
 c
hr
on
ic
 it
ch
C
h
ap
te
r 
3.
2
Introduction 
Itch is the most prominent physical complaint in chronic skin diseases such 
as atopic dermatitis (AD) and psoriasis (PS)1-3. Itch, and the related scratching 
behavior, can play an important role in the maintenance and exacerbation of 
dermatological disorders. It frequently becomes a principal problem in its own 
right due to a vicious circle of itch, scratching, and scratching-wounds that in turn 
produces itch4,5. Furthermore, itch has repeatedly been shown to negatively affect 
the quality of life of patients in aspects such as sleep disturbances, impairments of 
daily activities, work and psychosocial well-being2,3,6-8.
Although it is now well-known that itch is not a subliminal form of pain, 
and that both sensations have specific neurophysiological differences, itch shares 
numerous features with pain9-16. For example, both definitions emphasize an 
unpleasant sensory experience, which provokes a desire to scratch in itch17, and 
is associated with actual or potential tissue damage in the case of pain18. Similar 
to pain, itch can be induced by noxious signals19, transmissions through the 
spinothalamic tract16,20, and has a strong projection on the cortical motor system21.
In addition to the pathophysiological similarities between pain and itch, 
psychological processes are suggested to contribute to the maintenance and 
exacerbation of both chronic pain and chronic itch22,23. Specifically, cognitive, 
behavioral and physiological reactivity to pain have been known to unfavorably 
affect long-term outcomes in different chronic pain populations. In particular, there 
is relatively consistent evidence long-term pain outcomes are negatively affected 
by that worrying, avoidance of activity, and physiological pain responses of for 
example increased autonomic and muscular reactivity. These relations have further 
been shown to be relatively independent of disease severity and psychological 
vulnerability factors, such as negative affect and neuroticism24-32. In view of the 
similarities between itch and pain, corresponding psychological mechanisms may 
be responsible for the negative long-term outcomes in chronic itch. For example, 
preliminary evidence has suggested that worrying33,34, avoidance of activity35,36, 
and physiological reactivity37contribute to itch-related outcomes in patients with 
chronic skin diseases. Consequently, in accordance with known reactivity patterns 
in chronic pain, there may be a multidimensional reactivity pattern to chronic 
itch, which may have negative effects in patients with chronic itch, independent of 
disease characteristics and psychological vulnerability factors, such as neuroticism. 
The goal of this study was to explore the relative contribution of cognitive, 
behavioral, and physiological reactivity to itch -specifically worrying, avoidance of 
activity, and self-reported physiological itch responses- on itch-related outcomes 
in patients with chronic skin diseases. It was hypothesized that independent from 
neuroticism and disease status, patients with more itch reactivity in all three 
response systems would show higher levels of itch and scratching and a reduced 
disease-related quality of life. 
Methods
Participants
The patient sample consisted of 269 participants (128 with AD and 141 with PS) from 
the Department of Dermatology at the University Medical Centre St Radboud in 
the Netherlands. Inclusion criteria for the study population were a diagnosis of PS 
or AD and a minimum age of 15 years. Exclusion criteria were comorbid conditions 
(e.g. rheumatoid arthritis, malignancy, cardiac, respiratory, and renal insufficiency), 
pregnancy, and psychiatric or mental disturbances that would severely interfere 
with adherence to the study protocol. In addition, participants were asked to fill in 
the questionnaire only if they had suffered from itch during the previous four weeks. 
A total of 5% (n = 7) of the patients in the AD and 19% ( n = 27) in the PS sample did 
not report any itch symptoms. 
Eventually, 121 AD and 114 PS patients were included in the study (N = 235). 
Both the AD and the PS sample were predominantly composed of female (69.4% 
in the AD sample, 60.5% in the PS sample). The mean age in the AD sample was 34 
years (SD = 15 years, range 15-77). In the PS sample, the mean age was 48 years (SD 
= 14 years, range 17-84). In the AD sample, 2%, 62%, and 36% had (respectively) a 
primary, secondary, or tertiary education level. In the PS sample, these percentages 
were 12%, 68% and 20%, respectively. The mean duration of the disease was 19 
years for the AD sample (SD = 16 years) and 18 years for the PS sample (SD = 14 
years). Compared to the AD sample, the PS sample was older (t = -7.04, p < 0.01) 
and had a lower level of education (t = 4.65, p < 0.01). No differences between the 
samples were found with regard to gender or duration of the diseases. 
Measures
Demographic variables were assessed using a general checklist for age, gender, and 
educational level. The latter was measured using seven categories that can be 
classified as primary, secondary, and tertiary levels of education, representing on 
average 7, 12, and 17 years of formal education.
Cognitive, behavioral, and physiological responses to itch were assessed with validated 
scales used for pain in chronic pain populations.27 In these scales, the term “pain” 
was replaced by “itch”.
Cognitive and behavioral responses to itch were assessed with an analogous form 
of the Pain Coping Inventory27,38. This is an instrument that measures different 
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cognitive and behavioral ways of dealing with pain on a four-point Likert scale, 
ranging from 1 (rarely or never) to 4 (very frequently). Cognitive reactivity was 
assessed with the passive itch-coping scale, Worrying (9 items), which measures 
negative itch cognitions. Representative items were: “I start worrying when I itch” 
and “I think that the itch will get worse”. Behavioral reactivity was assessed with 
a composite score of the passive coping scales Resting and Retreating (12 items), 
measuring behavioral tendencies to restrict functioning and avoid environmental 
stimuli, respectively. Representative items in this scale were: “When I itch, I quit my 
activities” and “When I itch, I retreat to a restful environment”. Cronbach’s alpha 
in the present study was 0.83 for the cognitive and 0.87 for the behavioral reactivity 
to itch-scale. Physiological response to itch was measured with the physiological 
reactivity pain-scale27, a self-report measure partly derived from the Physiological 
Scale of the Pain Anxiety Symptoms Scale (PASS)39. Respondents were asked to 
indicate how frequently they experience physiological reactions to itch on a four-
point Likert scale ranging from 1 (rarely or never) to 4 (very frequently). The four 
items were: “When I itch, I become dizzy or weak”, “I start sweating when I itch”, “I 
become restless when I itch”, and “When I itch, I have a tight or tense feeling in my 
body”27. Cronbach’s alpha for this scale in the present study was 0.71.
Skin status was assessed with a nine-item scale, measuring the degree to which 
different parts of the body (face, haired head, neck, hands, arms, torso, legs, feet 
and genitals/ anus) are affected by the disease. The response categories were 
measured on a four-point Likert scale ranging from 1 (not) to 4 (totally)6,40. A total 
score for the affected area of the body was calculated by adding up the scores of the 
nine items. 
Itch was assessed with a four-item scale, that assesses the severity and frequency of 
itch6,40. The scale includes the following items with response categories on a four-
point Likert Scale ranging from 1 (rarely) to 4 (almost always): “My skin disease has 
been accompanied by itch during the past four weeks”, “I have had itch attacks 
during the past four weeks”, and “I suffered continuously from itch during the past 
four weeks”. The fourth item is measured on a Visual Analogue Scale, measuring the 
mean level of itch over the past four weeks on an eleven-point scale ranging from 
0 (no itch) to 10 (worst itch ever experienced). The total itch score was calculated by 
adding up the scores on all four items. For compatibility purposes, the score of the 
Visual Analogue Scale was first converted to a four-point scale. Cronbach’s alpha of 
the itch scale in the present study was 0.82. 
Scratching was assessed with a three-item scale, dealing with the amount of 
scratching during the previous four weeks on a four-point Likert scale with the 
following items: “I scratched during the past four weeks” (ranging from 1 [rarely] to 
4 [ almost always]), “I scratched with my nails during the past four weeks” (ranging 
from 1 [rarely] to 4 [almost always]), and “The longest time I spent continuously 
scratching” (ranging from 1 [less than half a minute] to 4 [more than five minutes]). 
The total scratching score was calculated by adding up the scores on all three items. 
Cronbach’s alpha for this scale was 0.74. 
Disease-related quality of life was measured with the Dermatological Life Quality 
Index (DLQI)41, a ten-item scale that assesses the general impact of dermatological 
diseases on several areas of daily life (e.g. work/study, homework, leisure time, 
sexuality, relationships with acquaintances, friends and family members). Higher 
scores on this scale indicate a reduced disease-related quality of life. Cronbach’s 
alpha in the present study for this scale was 0.88.
Neuroticism was measured with a Dutch version of the Eysenck Personality 
Questionnaire42,43. Cronbach’s alpha in the present sample was .86.
Statistics
Pearson correlation coefficients were calculated between the cognitive, behavioral, 
and physiological reactivity of itch and the amount of itch, scratching, and the 
disease-related quality of life. Sequential regression analyses were then performed 
to study the relative contribution of the response systems to itch, scratching, 
and disease-related quality of life, after controlling for confounding variables. 
Demographic variables (age, gender, educational level, duration of the disease), 
type of diagnosis, neuroticism, and skin status were entered as control variables in 
steps one to four, followed by the response systems in step five. Results were initially 
calculated for both disease groups separately. However, because the results from 
the correlation analysis were about the same for both participants groups, they 
are presented together in all analyses. All statistical analyses were carried out with 
the SPSS 12.0 Windows statistical package and a minimum of 229 patients sharing 
complete data set.
Results
Itch intensity and disease status
The majority of patients suffered from relatively high levels of itch. Of all 
participants, only 6.9% had very low scores of itch (a score of < 4 on a scale ranging 
from 0-16), whereas more than half of the patients (58.2%) suffered form relatively 
high levels of itch (scoring > 8 on a scale ranging from 0-16). These percentages 
were about the same in both patient groups of AD and PS. A similar picture emerged 
from the scale that measured skin status, showing that in the majority of all patients 
(74.5%) at least one or more body areas were strongly affected by the skin disease.
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Correlates of itch reactivity
Pearson correlation coefficients indicated that all response systems had similar, 
moderate correlations with itch, scratching and disease-related quality of life (see 
Table 1), indicating more cognitive, behavioral, and physiological reactivity to itch 
in patients with higher levels of itch and scratching and a reduced disease-related 
quality of life. In addition, all response systems were significantly related to more 
neuroticism (r = 0.35 - 0.43, p < 0.01) and a worse skin status (r = 0.16 - 0.24,  
p < 0.01). Furthermore, Pearson correlation coefficients between self-reported 
cognitive, behavioral, and physiological reactivity patterns indicated significant 
similar, positive correlations between the different response systems (r = 0.55 - 0.65, 
p < 0.01). 
Table 1. Pearson correlation coefficients between itch-related outcomes.
* p< 0.05,  ** p < 0.01
1 Dermatology Life Quality Index
2 Male = 0, Female = 1
3 Atopic Dermatitis = 1, Psoriasis = 2
Itch reactivity as a predictor for itch-related outcomes
As the concepts of cognitive, behavioral and physiological reactivity are likely to 
overlap to some extent, sequential regression analyses were performed to examine 
the relative contribution of the different response systems to itch-related outcomes. 
Specifically, these were itch, scratching, and disease-related quality of life after 
controlling for confounding demographic variables (age, gender, educational level, 
duration of the disease), type of diagnosis (AD or PS), skin status, and neuroticism 
(steps one - four). Results indicate that, after controlling for these confounding 
factors, the response systems explained 5% of the variance in both itch (Fchange 
= 5.00, p < 0.01) and scratching (Fchange = 4.83, p < 0.01) and 16% of the variance 
of the disease-related quality of life (Fchange = 23.86, p < 0.01). Beta coefficients 
for the entire model demonstrated that cognitive reactivity significantly predicted 
higher levels of itch (t = 2.50, p < 0.01). Self-reported physiological reactivity 
significantly predicted more scratching (t = 2.53, p < 0.05), and cognitive (t = 4.45, p 
<0 .01) as well as behavioral reactivity (t = 3.59, p < 0.01) significantly predicted  
a reduced disease-related quality of life (Table 2).
Table 2. Sequential regression analyses predicting itch, scratching and disease-related quality  
of life.
* p < 0.05, ** p < 0.01   1 Dermatology Life Quality Index
a probability level of t-test  2 Age, gender, educational level, duration of the disease
b probability level of Fchange 3 Atopic Dermatitis = 1, Psoriasis = 2
  Itch Scratching DLQI 1  
Control variables
Demographic variables   
		 	•		Age	 -0.04	 -0.18**	 -0.02
		 	•	Gender	2    0.10 0.15* 0.14*
		 	•	Education	 -0.03	 0.03	 -0.08
		 	•	Duration	of	the	disease	 -0.02	 0.01	 0.04
Diagnosis 3  -0.15* -0.24** -0.13*
Neuroticism 0.13* 0.18** 0.36**
Skin status 0.48** 0.42** 0.46**
   
Itch reactivity   
		 	•	Cognitive	 0.35**	 0.34**	 0.54**
		 	•	Behavioral	 0.30**	 0.29**	 0.53**
		 	•	Physiological	 0.33**	 0.38**	 0.48**
  Itch Scratching DLQI1 
  Betaa  R2b  Betaa  R2b  Betaa  R2 b 
Control variables (step 1-4)
Demographic variables 2   0.01  .06**  0.03
Diagnosis 3  -0.11 0.02* -0.08 .02* 0.01 0.02*
Neuroticism -0.07 0.01 -0.03 .02* 0.07 0.11**
Skin status 0.46** 0.25** 0.40** .19** 0.35** 0.19**
   
Itch reactivity (step 5)   
		 	•	Cognitive	 0.20*	 	 0.07	 	 0.31**	
		 	•	Behavioral	 0.01	 	 0.02	 	 0.22**	
		 	•	Physiological	 0.10	 	 0.20*	 	 0.07
 
Total R 2   0.34  .33  0.51
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Discussion 
The pathophysiology of chronic skin diseases alone seems unable to account for the 
long-term outcomes of chronic itch, raising the question whether a psychological 
model as described for chronic pain may also apply to chronic itch22,23. In chronic 
pain, a maintaining role of cognitive, behavioral, and physiological reactivity to 
pain -specifically worrying, avoidance of activity, and physiological responses- 
has been shown for pain-related outcomes24-32. Our explorative study shows that 
corresponding reactivity patterns to chronic itch seems to be similarly relevant for 
patients suffering from chronic itch. 
 In line with cognitive, behavioral, and physiological reactivity to chronic pain27, 
all response systems demonstrated relatively uniform and significant correlations 
to measures of disease severity and neuroticism. This suggests that they are all 
influenced by the actual skin status and have a common, underlying predisposition 
to vulnerability to stress. Furthermore, correlations between the three response 
systems indicate that these systems are related and possibly enhance each other. 
Independent of relationships to neuroticism and skin status, sequential regression 
analyses further show that all response systems significantly predicted itch, 
scratching, and disease-related quality of life, suggesting that they can have an 
unfavorable effect on itch-related outcomes in patients suffering from chronic itch. 
The cognitive response pattern of worrying was specifically related to the 
increased intensity of itch and reduced disease-related quality of life in sequential 
regression analyses. In patients with chronic pain, worrying is known to have 
a negative influence on long-term pain outcomes24,25,29,32. Previous studies in 
patients with chronic skin diseases suffering from chronic itch also showed that a 
considerable number of these patients experience high levels of worrying thoughts, 
which affected disease-related outcomes33,34. In line with chronic pain patients, 
worrying about itch may bring about a preoccupation with the patients’ bodily 
sensations of itch. Consequently, patients may become more sensitive to the 
perception of itch and may experience their itch as more intense. 
In addition to cognitive reactivity, behavioral reactivity to itch also predicted 
the disease-related quality of life in sequential regression analyses, showing that 
more avoidance of activity may result in a reduced disease-related quality of life. In 
behavioral approaches to pain processing, it is well-known that avoidance of activity 
has a negative effect on the maintenance and exacerbation of chronic pain26,27,29-
32. In line with our study, studies by Scharloo et al35,36 showed that avoidance 
behavior was unfavorably related to disease outcomes, such as physical health 
and disease-related quality of life, in patients with chronic skin diseases that are 
frequently accompanied by itch. In contrast to acute pain, which primarily evokes 
an immediate behavioral response to withdraw from the painful stimulus or activity, 
acute itch is predominantly a trigger for heightened physical activity of particularly 
scratching. However, the behavioral response to chronic itch usually causes patients 
to withdraw from activities or avoid daily activities, which may lead to a reduced 
quality of life in the long-term.
Finally, self-reported physiological responses to itch were a significant predictor 
of scratching in sequential regression analyses. In patients with chronic pain, 
physiological reactivity patterns have been shown to manifest themselves in 
increased autonomic and muscular reactivity as well as the sensitization of central 
structures28-30 and to have long-term effects on chronic pain, leading to increased 
pain in the longer term27. Preliminary results also suggest stress- or itch-related 
patterns of physiological reactivity in patients with chronic skin diseases37. Based on 
predispositions or respondent learning processes (or both), physiological responses 
to itch might develop in a chronic condition of a consistent, habitual pattern of 
reactivity to itch, which may manifest itself as a desire to scratch and scratching 
behavior.
Some limitations of this study should be kept in mind when interpreting 
the results. Due to the cross-sectional design of our study, inferences of causal 
relationships between measures of itch reactivity and itch-related outcomes are 
inappropriate. Prospective research will gain a better insight into the nature of 
the relations studied. In addition, the relations between measures of responses 
to itch and itch-related outcomes may be influenced by the use of self-reported 
measures. For example, similar to chronic pain patients, the question arises whether 
the self-reported measure of physiological reactivity truly represents symptom-
specific physiological reactivity. Due to the subjective nature of this measure, it 
could, for example, be argued that this measure may be affected by attentional 
or interpretational processes, such as hypervigilance, or may represent a generic 
heightened physiological response27,44. In addition, self-reported itch reactivity 
factors such as worrying, might also be influenced by a general disposition to worry, 
which in turn has been shown to negatively affect the outcomes of dermatological 
treatment33. For future research, it would be of interest to investigate possible 
neuropathological differences between itch sensations of different patient groups 
and it’s potential influence on the itch quality and response patterns of these 
groups. 
Despite the limitations, the results of this study suggests that cognitive, 
behavioral, and physiological reactivity to chronic itch (which are analogue to 
known reactivity patterns in chronic pain) are related to itch-related outcomes in 
chronic skin diseases. Consequently, a psychological model as described for chronic 
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pain appears to be a useful starting-point for study of the maintaining mechanisms 
of chronic itch.
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Abstract
Background
There is increasing support that stressors contribute to the severity of chronic 
inflammatory diseases, such as psoriasis. Due to a lack of prospective studies, 
evidence for a possible causal relationship is lacking in patients with psoriasis. 
Objective
To investigate the prospective relationship between daily stressors and changes 
in disease severity (PASI) and itch in patients with psoriasis, and to determine the 
influence of individual reactivity factors of worrying, scratching and avoidance 
behavior on this relationship.
Methods 
Patients were followed up for six months with monthly clinical and self-reported 
measures of daily stressors, itch, disease severity, and individual reactivity factors. 
Data from 62 patients were suitable for analyses. 
Results
Daily stressors were significantly associated with an increase in disease severity and 
itch four weeks later, but only at moments when patients experienced a high level of 
daily stressors. This relationship between daily stressors and disease outcome was 
further increased in patients characterized by high levels of worrying and scratching. 
Conclusion
Daily stressors influence disease outcome in patients with psoriasis, particularly 
at highly stressful periods. Patients with high levels of worrying and scratching are 
most vulnerable to the influence of stressors on their psoriasis.
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Introduction
Many patients (37-88%) with psoriasis believe that there is a relationship between 
stressors and their skin disease1-7, and this relationship has received increasing 
attention over the years. For example, over 60% of patients with psoriasis 
retrospectively report having experienced stressful life events in the month before 
exacerbation of the disease8-10. In addition, there is some preliminary prospective 
evidence from case studies based on five patients that stressors might be positively 
associated with disease severity in patients with psoriasis11,12. While these findings 
suggest that stressors may influence the course of disease outcome in patients with 
psoriasis, to date there is a lack of prospective studies of the relationship between 
stressors and disease outcome in these patients. Evidence for a possible causal 
relationship between stressors and disease outcome is thus far lacking.
The relationship between stressors and disease outcome may be 
influenced by patient characteristics13. For example, patients with psoriasis who 
consider themselves highly reactive to stressful life events or their disease have 
higher scores on measures of disease outcome and have lower cortisol levels 
after an experimentally induced stressful experience than patients who do not 
believe themselves to be highly reactive to stress5,7,14. This indicates that patients 
might differ in their reactivity to stressful life events and the related physiological 
response to stress, which may influence the disease-related outcome. In general, 
the reactivity of patients to stressors or disease consists of both cognitive and 
behavioral aspects. Perseverative worrying, a cognitive response, is a common 
response to disease or stressful events and has been reported to prolong stress-
related affective and physiological activation of, for example, endocrine and 
immune systems15. Consequently, worrying could influence physical well-being 
through several psychological and physiological pathways. In patients with 
psoriasis, worrying has indeed been shown to negatively influence disease severity 
and itch, particularly in patients with high levels of worrying16-18. Additionally, the 
behavioral factor of enduring avoidant behavior has been related with higher levels 
of itch and other disease-related outcomes in patients with psoriasis1,17. This is in 
line with findings for other chronic (skin) conditions. For example, avoidance in 
response to daily stressors has been associated with itch in patients with atopic 
dermatitis19. It is also well known that avoidance of activity has a negative effect on 
the maintenance and exacerbation of chronic pain20-22. Although the acute effects 
of skin diseases predominantly trigger patients to become physically active by 
particularly scratching, the long-term behavioral response is usually withdrawal 
from activities or avoidance of daily activities in order to prevent an exacerbation 
of symptoms. Scratching in response to itch is a particularly important feature of 
skin diseases accompanied by itch, as is reflected by the definition of itch as an 
unpleasant sensation that evokes the desire to scratch23. Although early textbooks 
described psoriasis as a non itching skin disease, more recent data showed that 
approximately 60-80% of all patients with psoriasis report experiencing itch6,24, 
with the highest percentage found among patients seen on dermatological wards6. 
The immediate reinforcement of scratching is the reduction of itch, although 
patients with enduring itch due to chronic skin diseases may persist in their 
scratching behavior (even until the skin bleeds), resulting in a vicious itch-scratch-
itch cycle. Due to this vicious cycle, scratching may become a problem in its own 
right. Moreover, scratching induces several physiological responses, such as the 
secretion of several immunological markers, for example interferon, which has 
been described to mediate the disease severity of psoriasis. Consequently cognitive 
and behavioral reactivity of specifically worrying, scratching or avoidance behavior, 
could directly affect the disease outcome of chronic skin diseases. Additionally, 
these reactivity factors might also influence the relationship between daily stressors 
and disease outcome. 
To investigate the possible relationship between stressors and disease 
severity in daily life, a prospective design with repeated measurements over time 
is required. When studying a possible significant and relevant influence of daily 
stressors, it is further important to investigate the relationship with disease severity 
at such a moment when the level of daily stressors is relatively high25. Although a 
prospective study design with repeated measurements does not guarantee that 
participants will experience relatively high levels of daily stressors, over a six month 
period it is likely that a person will experience increased levels of daily stressors at 
some point. However, as far as we know, there are not yet prospective studies about 
the relationship between daily stressors and psoriasis, particularly no studies that 
focus on moments when patients actually report relatively high levels of stressors.
The aim of the current study was to investigate the relationship between the 
experience of daily stressors and the change in disease outcome (disease severity 
and itch) four weeks later in patients with psoriasis. Furthermore, we investigated 
the influence of individual cognitive and behavioral reactivity on the change in 
disease severity and itch. We hypothesized that only at moments of relatively high 
levels of daily stressors, there would be a relationship between stressors and an 
increase in itch and disease severity four weeks later. Moreover, we expected that 
individual reactivity factors of cognitive and behavioral reactivity (specifically 
worrying, scratching and avoidance behavior) would be positively associated with 
the change in disease severity and itch, and would possibly affect the relationship 
between levels of daily stressors and changes in disease outcomes. 
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Materials and Methods
Participants and procedure
Patients were recruited from the Departments of Dermatology at the University 
Medical Centre St Radboud, Nijmegen and the Canisius Wilhelmina Hospital, 
Nijmegen, the Netherlands. Inclusion criteria were a diagnosis of psoriasis, a 
minimum age of 18 years and a stable medication regimen in the three months prior 
to the start of the study (no change of the type of systemic medication or start of 
phototherapy). Exclusion criteria were comorbid conditions (such as rheumatoid 
arthritis, psoriatic arthritis, malignancy, cardiac, respiratory and renal insufficiency), 
pregnancy and psychiatric or mental disturbances that would severely interfere with 
adherence to the study protocol. Patients who used antidepressant medication were 
also excluded. Patients whose medication regimen (type of systemic medication or 
start of phototherapy) changed during the study were also excluded. Participants 
were followed up over six months with monthly clinical and self-reported measures 
of disease severity and itch, respectively. Exceptions were made for seven patients 
who stopped the study after four months due to changes in medication regimen 
(five due to a change in systemic medication, one due to the start of antidepressant, 
one due to the start of phototherapy). Additionally, self-reported daily stressors and 
individual reactivity factors were assessed monthly. 
Measures
Demographic variables were assessed using a general checklist for age, gender, and 
educational level. The latter was measured using seven categories that can be 
classified as primary, secondary and tertiary levels of education, representing on 
average 7, 12, and 17 years of formal education.
Disease outcomes were assessed with measures of disease severity and itch. Disease 
severity was assessed with the Psoriasis Area and Severity Index (PASI)26. Itch was 
assessed with the validated four-item scale from the Impact of chronic Skin diseases 
on Daily Life questionnaire (ISDL), which assesses the severity and frequency 
of itching during the past four weeks27. The scale includes the following items 
with response categories on a four-point Likert scale, “My skin disease has been 
accompanied by itch during the past four weeks”, “I have had itch attacks during 
the past four weeks” and “I suffered continuously from itch during the past four 
weeks”. The mean level of itch in the past four weeks was measured on a Visual 
Analogue Scale (VAS; 0 = no itching; 10 = worst itching ever experienced). The total 
itch score was calculated by adding together the scores on all four items, after 
converting the score of the VAS to a four-point scale. 
Daily stressors were assessed with a short 49-item version of the Everyday Problem 
Checklist (EPCL)28,29. This validated questionnaire includes items such as “You had 
to wait long for an appointment”, “You blundered in company”, or “Important 
belongings got lost”. When patients answered that they experienced the event, they 
indicated the intensity of this events, ranging from 0 (“no impact at all”) to 3 (“very 
high impact”). The total score for experienced daily stressors was calculated by 
adding up all items.
Cognitive and behavioral reactivity were assessed with validated self-reported 
questionnaires. The cognitive and behavioral factors of worrying and avoidance 
behavior were measured with an adapted version of the Pain Coping Inventory 
(PCI), in which the term “pain” is replaced by “itch”17,30. This instrument measures 
different ways of dealing with symptoms of itch on a 4-point Likert scale ranging 
from 1 (“rarely or never”) to 4 (“very frequently”). Worrying was measured with 
a 9-item scale measuring negative disease cognitions. Items on this scale ask 
patients e.g. how often they worry about their itch. A representative item is “I think 
that the itch of my psoriasis will get worse”. Avoidance behavior was assessed with 
a composite score of the scales of Resting and Retreating (12 items), measuring 
behavioral tendencies to restrict functioning and avoid environmental stimuli, 
respectively. Items on these scales ask e.g. about the frequency of quitting activities 
and retreating to a restful environment due to their itch. Scratching was assessed 
with the scratching scale of the Impact of chronic Skin diseases on Daily Life 
questionnaire (ISDL)27. This scale determines the amount of scratching during the 
previous four weeks on a 4-point Likert scale with the following items: “I scratched 
during the past four weeks”, “I scratched with my nails during the past four 
weeks” (ranging from “rarely” to “almost always”) and “The longest time I spent 
continuously scratching” (“less than half a minute” to “more than five minutes”). 
The total scratching score was calculated by adding up the scores on all three items. 
Statistics
To investigate the influence of the highest and lowest moment of daily stressors on 
disease severity within the 6-months period, the month in which the participant 
reported the most daily stressors (highest EPCL score) as well as the month in which 
they reported the least daily stressors (lowest EPCL score) was determined for all 
participants. To examine the relationship of daily stressors on the change in disease 
severity and itch in both months, prospective relationships between daily stressors 
and changes in disease outcome four weeks later were examined by calculating 
Pearson correlation coefficients between the EPCL daily stressor scores and the 
change in disease severity (PASI) and itch. For this purpose residual gain scores were 
used to measure the change in PASI and itch. These scores take into account the 
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individual baseline levels and control for regression to the mean effects31. Residual 
gain scores were calculated by regressing the outcome measure (e.g. PASI score) 
at the follow-up assessment after four weeks on the score of this measure at the 
moment when patient reported experiencing the most as well as the least daily 
stressors. Furthermore, to investigate the possible influence of individual reactivity 
factors, we calculated Pearson correlation coefficients between the individual 
reactivity factors of worrying, avoidance behavior, and scratching and the change in 
measures of disease outcome (disease severity and itch). Subsequently, to examine 
possible effects of these individual reactivity factors on the relationship between 
daily stressors and changes in disease outcome, centered interaction terms between 
the predictor (experience of daily stressors) and the reactivity factors (cognitive 
and behavioral) were calculated32. Next, we determined the Pearson correlation 
coefficients between these interaction terms and the change in disease severity 
and itch. Finally, all predictors were entered in a sequential regression analyses to 
determine the relative influence of all predictors on the change in disease outcome 
(disease severity and itch) four weeks later. After controlling in the first step for the 
level of disease severity and itch when patients reported the most daily stressors, 
daily stressors and individual reactivity factors were entered in the following steps 
(step two and three), followed by the centered interaction terms in the final fourth 
step. The relative contribution of the predictors in the regression analyses were 
compared by standardized beta’s and t-tests. All statistical analyses were carried out 
with the SPSS 14.0 Windows statistical package with a complete data set of at least 
95% of all assessments. 
Results
Patient characteristics
A total of 76 consecutive patients participated in the study. Eventually, data of 
14 patients were not suitable for analyses: eight participants dropped out before 
the six month follow-up (three persons because of time constraints, two persons 
because of occurring comorbid physical health problems during the study period 
[knee surgery and heart failure], and three for personal reasons [divorced, n = 1 
and illness in the family, n = 2]), two because of changes in systemic medication, 
and four because they started with phototherapy. Consequently, the final sample 
consisted of 62 patients with a mean age of 52.3 years (SD 13.2 years, range 21.9-
79.7) at start of the study. Of all participants, 72.6% were male and 27,4% were 
female. Furthermore, 4.8%, 66.1% and 29.1% had a primary, secondary, or tertiary 
education level, respectively. Student’s t-tests and Chi square tests showed no 
significant differences between the patients in the final sample and the patients who 
did not complete the study in terms of age, gender, disease duration, educational 
level, measures of disease severity, itch, daily stressors, and individual reactivity 
factors at the start of the study (data not shown).
Relationship between daily stressors and disease outcome
Mean levels of disease severity, itch, and daily stressors in the month in which 
patients experienced the highest and lowest levels of daily stressors are presented in 
Table 1. As was expected by our analyses of the highest or lowest stress levels within 
the 6-months period, there was a significant difference in the level of daily stressors 
between the moments of highest and lowest reported daily stressors. Furthermore, 
when patients reported the highest level of daily stressors, they also experienced 
significantly more itch and more severe disease than when they reported the lowest 
level of daily stressors. 
Pearson correlation coefficients further showed that when patients reported 
the most daily stressors, there was a positive, significant correlation between daily 
stressors and the increase in disease severity (PASI) and itch four weeks later (see 
stressors in Table 2). In contrast, daily stressors were not significantly associated 
with the change in disease severity and itch four weeks after patients reported the 
least daily stressors (data not shown). None of the demographic variables (gender, 
age and educational level) were further related to the change in disease severity 
(PASI) or itch at this moment of highest or lowest stress (data not shown).
Table 1. Level of daily stressors and disease outcome (means, standard deviations and paired 
samples t-tests) at the moments patients reported the most and the least daily stressors. 
Relationship between cognitive and behavioral reactivity factors and  
disease outcome
To investigate the possible influence of individual reactivity factors on the change 
in disease severity (PASI) and itch four weeks later, Pearson correlation coefficients 
were calculated between the individual reactivity factors of worrying, scratching, 
and avoidance behavior and the change in measures of disease outcome (disease 
severity and itch). When patients experienced the most daily stressors, both 
  Most daily stressors Least daily stressors 
Daily stressors 16.8 (SD 10.9) 5.1 (SD 5.8) t = 13.6, p < 0.001
Disease severity 7.0 (SD 4.4) 6.0 (SD 4.3) t = 2.5, p < 0.05
Itch 6.3 (SD 3.0) 5.6 (SD 3.0) t = 2.0, p < 0.05
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worrying and scratching were positively correlated with the increase in itch four 
weeks later (see individual reactivity factors in Table 2). No significant relationships 
were found between avoidance behavior and the change in itch as well as between 
worrying, avoidance behavior, and scratching with the change in disease severity 
(PASI). In line with our hypothesis, when patients experienced the least daily 
stressors, neither worrying, scratching, nor avoidance behavior was found to be 
correlated with the change in disease severity and itch four weeks later (data not 
shown).
Effects of cognitive and behavioral reactivity factors on the relationship between 
daily stressors and change in disease outcome
To examine the effects of individual reactivity factors on the relationship between 
daily stressors and change in disease outcome (disease severity and itch), centered 
interaction terms between the predictor (daily stressors) and the reactivity factors 
(cognitive and behavioral) were calculated. When patients reported the most 
daily stressors, results indicated that the interaction between daily stressors and 
worrying was significantly correlated with an increase in itch four weeks later (see 
interaction terms in Table 2). There was also a tendency for a significant relationship 
between this interaction term and an increase in disease severity (PASI; p = .06). 
In addition, the interaction between daily stressors and scratching significantly 
predicted an increase in both disease severity and itch four weeks later. No 
significant correlations were found for the interaction term between daily stressors 
and avoidance behavior. As expected, when patients reported the least daily 
stressors, no significant relationships or tendencies were again found between any 
of the interaction terms and changes in disease outcome four weeks later (data not 
shown).
Table 2. Pearson correlation coefficients between the change in disease outcome and the study’s 
predictors when patients reported the most daily stressors.1
* p < .05, ** p < . 01
1 A positive correlation indicate that a high level of daily stressors, or individual reactivity factors is associated 
with an increase in disease severity / itch.
Relative contribution of all predictors to the change in disease outcome
To determine the relative contribution of all predictors to the change in disease 
outcome (disease severity and itch) four weeks later, sequential regression analyses 
were conducted when patients reported the most daily stressors. After controlling 
in the first step for the level of disease severity and itch when patients reported 
the most daily stressors, daily stressors and individual reactivity of worrying and 
scratching were entered in the following steps (step two and three), followed by the 
centered interaction terms in the final fourth step. 
For the change in disease severity, all steps significantly added to the 
explained variance of the change in disease severity after four weeks, with exception 
of the step in which the reactivity factors were added (see Table 3). The disease 
severity explained 76% of the increase in disease activity after four weeks. The 
daily stressors and the interaction terms additionally explained 2% and 3% of 
the increase in disease severity, respectively. Regarding itch, all four steps added 
significantly to the explained variance of the change in itch after four weeks (see 
Table 3). The level of itch when patients reported the most daily stressors explained 
  Change disease severity Change itch 
Stressor  
Daily stressors .28* .26*
  
Individual reactivity factors  
Worrying .07 .27*
Scratching .16 .41**
Avoidance behavior .05 .09
  
Interaction terms  
Daily stressors x worrying .29 .32*
Daily stressors x scratching .38** .41**
Daily stressors x avoidance .06 .09
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69% of the increase in itch. The daily stressors, reactivity factors, and interaction 
terms additionally explained 2%, 8%, and 3% of the increase in itch, respectively. 
When the relative contribution of the predictors were compared by standardized 
beta’s, scratching significantly predicted higher levels of itch four weeks later  
(t = 3.62). 
Table 3. Sequential regression analyses predicting disease outcome four weeks later, when patients 
reported the most daily stressors.
*p < 0.05  ** p < 0.01
Discussion
The present study is one of the first prospective studies to examine the influence of 
daily stressors on disease severity and itch in patients with psoriasis. Results showed 
daily stressors to be associated with an increase in disease severity of the PASI and 
itch four weeks later. As expected, this relationship was only present when patients 
experienced high levels of daily stressors and not when patients experienced low 
levels of daily stressors. Furthermore, individual reactivity factors of worrying 
and scratching were significantly related to increases in itch four weeks later. 
These reactivity factors also statistically moderated the relationship between daily 
stressors and disease outcome (itch and disease severity) showing that patients who 
are characterized by more worrying and particularly more scratching at moments of 
relatively high levels of daily stressors have a greater increase in disease outcome 
after four weeks than patients with lower scores for these reactivity factors. 
Our results are in line with those of other studies focusing on the 
relationship between stressors and disease outcome. For example, significant 
prospective relationships between daily stressors and an increase in disease 
severity have been reported in patients with atopic dermatitis19,33. For other chronic 
inflammatory diseases, such as rheumatoid arthritis, prospective relationships 
between daily stressors and disease severity have also particularly been found at 
moments when patients report heightened levels of stressors25,34,35. These findings 
support the idea that the experience of a relatively high level of daily stressors can 
influence the course of chronic inflammatory diseases, including psoriasis. 
We also found the cognitive reactivity of worrying and scratching to 
be significantly and positively related with changes in itch after four weeks. 
Additionally, the interaction terms between daily stressors and the reactivity factors 
of worrying and scratching predicted an increase in disease outcome (both itch 
and disease severity). Our findings that high levels of worrying and scratching are 
associated with an increase in disease outcome correspond with those of previous 
studies. For example, patients with high levels of worrying have a significantly 
slower response to photochemotherapy as treatment for psoriasis in comparison to 
patients with lower levels of worrying16. Previous studies also showed a relationship 
between scratching and disease severity27. The question arises why the individual 
reactivity factors worrying and scratching were particularly associated with itch. One 
explanation might be that within our study population, disease severity was more 
stable than itch over time. Consequently, for disease severity there was less variance 
to be explained by factors other than disease severity. Furthermore, the self-report 
instruments we used specifically asked about the patient’s reactivity to the physical 
symptoms of itch. It would be interesting for future research to investigate patients’ 
reactivity to other specific aspects of psoriasis. 
Avoidance behavior was not associated with changes in itch or disease 
severity. Acute itch is predominantly a trigger for increased physical activity 
of particularly scratching. However, the long-term behavioral response to 
chronic itching is usually withdrawal from activities or to avoid daily activities. 
Consequently, avoidance behavior might only influence long-term disease outcome. 
Studies of other chronic inflammatory diseases have shown that avoidance behavior 
in particularly is related to longer-term disease outcome in time, for example, after 
one, three and even five years36. 
Stressors can generally be divided into major life events (e.g. the death of 
a spouse) and daily stressors (e.g. running late for an appointment or losing your 
  Disease severity Itch after 4 weeks
  after 4 weeks
  B ∆R2 B ∆R2
1. Disease outcome 
   Disease severity .85** .76**
   Itch   .60** .69**
2. Daily stressors .11 .02* .04 .02*
3. Reactivity factors
    Worrying -.02  .10
    Scratching .02  .30** 
4. Interaction terms  .03* .03*
    Daily stressors x worrying .04  .05
    Daily stressors x scratching .15  .13 
Total R2  .81  .82
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keys). Although many studies of stressors and health have focused on major life 
events, the impact of daily stressors have been found to be a substantially better 
predictor of health outcome than major life events29,37. Nevertheless, many different 
questionnaires exist in measuring stressors, each with its own specific focus: e.g. 
interpersonal daily stressors, disease-related daily stressors or the perceived stress 
of life events. Further research should show whether our findings concerning daily 
stressors in relation to disease outcome also apply to other measures of daily 
stressors.
 When interpreting the results of the study, several limitations have to be 
kept in mind. Although the patients who completed the study did not differ from 
the patients who did not complete the study, there could have been a selection 
bias because more than half of our study population consisted of older males. 
Furthermore, in order to control for medication effects, we included only patients 
whose medication regime was stable in the three months before the start of the 
study. Thus the patient sample was quite homogeneous, which could explain the 
relatively moderate PASI scores observed. Moreover, during the study we had to 
exclude only six patients because their medication regimen was changed, which 
suggests that disease severity showed less variability than usual. Additionally, we 
cannot exclude that the design of the study with repeated assessments might have 
influenced patients’ attitudes and behavior, such as compliance with applying 
topical medication. 
 The present study is one of the first prospective studies to show a 
relationship between daily stressors and changes in disease outcome in patients 
with psoriasis. Patients with high levels of worrying and scratching seem most 
vulnerable to the influence of daily stressors, particularly in their sensation of itch. 
Although our results should be replicated, our findings indicate that the possible 
effect of daily stressors on disease outcome should be noticed within daily practice, 
particularly when patients are going through stressful periods and for patients with 
high levels of worrying and scratching who are most vulnerable to the influence of 
stressors on their disease.
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The thesis has two main parts. The first part (chapters 2.1, 2.1, and 2.3) describes 
studies performed to gain knowledge about the impact of skin diseases on 
patients in general practice. For this purpose, the prevalence of skin diseases in 
general practice and the use of health care facilities were investigated. In addition, 
studies were performed to examine the experience of physical symptoms and 
the psychosocial well-being of general practice patients with skin diseases. The 
second part (chapters 3.1, 3.2, and 3.3) describes studies performed to examine 
biopsychosocial predictors of disease severity and itch with emphasis on the 
influence of daily stressors and psychological individual reactivity factors. Findings 
will be separately summarized for both parts.
Impact of skin diseases on patients in general practice 
The first part of the thesis describes studies based on data from the Continuous 
Morbidity Registration (CMR) of the Department of General Practice, Radboud 
University Medical Centre. The registration covers a relatively stable population of 
12 000 citizens that is representative of the general Dutch population. In addition to 
the registry data, questionnaires about health care use and physical, psychological 
and social well-being were administered to patients who had been registered with a 
skin disease within the CMR in the preceding 12 months.
In the first study (chapter 2.1), the prevalence and incidence of skin 
diseases in general practice were examined, as was the use of health care facilities. 
Overall, skin diseases accounted for 12.4% of all diseases seen by the participating 
general practitioners. As expected, the prevalence of psoriasis and atopic dermatitis 
was high. Compared with earlier Dutch data on the prevalence of skin diseases, 
descriptive data indicated a possible increase in the prevalence of atopic dermatitis, 
seborrheic dermatitis, psoriasis, diseases of the hair, and seborrheic keratosis. 
The questionnaire survey about health care use showed that more than 80% of all 
patients had contacted their general practitioner for their skin disease during the 
previous year. Moreover, 65% of the patients were treated solely by their general 
practitioner. Patients with a more severe skin disease, more symptoms of itch, 
and a lower disease-related quality of life made more frequent use of health care 
services (general practice, specialized care by particularly dermatologists and 
complementary or alternative medicine) than did patients with better scores on 
these measures. 
 In the following chapter (2.2), the prevalence of accompanying physical 
symptoms of itch, pain, and fatigue was studied among patients with skin diseases 
in general practice. Results showed that a substantial number of patients with 
skin diseases experienced physical symptoms: more than 50% of the patients 
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reported symptoms of itch and fatigue, and 25% reported these symptoms as being 
relatively severe. Patients with pruritus, psoriasis, and different forms of dermatitis 
particularly reported itch and fatigue. Pain was less frequently reported and was, 
on average, also less intense. Physical symptoms were most strongly associated 
with worse self-reported disease severity and a lower disease-related quality of 
life. Additionally, modest but significant correlations were found between physical 
symptoms and comorbidity and between physical symptoms and the demographic 
variables of higher age, female gender and lower educational level. 
 In the final study of this part (chapter 2.3), the psychosocial well-being 
of patients with skin diseases in general practice was compared with that of the 
general population. Results showed that patients with skin diseases in general 
practice have a lower psychosocial well-being than the general population. The 
psychosocial impairments were particularly present in patients with more severe 
and longer-lasting skin disease, more accompanying physical symptoms, and other 
chronic morbidities. A considerable number of patients (about 15%) with skin 
diseases appeared to be at risk of developing severe psychological impairment such 
as clinical depression.
Biopsychosocial predictors of itch and disease severity
The aim of the studies of the second part of this thesis was to assess biopsychosocial 
predictors of disease outcome in patients with skin diseases. First, the evidence for 
a biopsychosocial model for chronic itch was reviewed, focusing in particular on 
evidence for the effects of personality characteristics, external stressors, cognitive, 
behavioral and social factors, and the possible mediating role of physiological 
processes (chapter 3.1). This review showed that overall findings are in favor of a 
biopsychosocial model of chronic itch. With regard to internal personality factors, 
research so far has generally not been able to show that patients with skin diseases 
have distinct personality characteristics. Contrary, preliminary evidence suggests 
a possible relationship between itch and the experience of stressors. Furthermore, 
evidence exists that cognitive and behavioral factors are associated with the 
experience of itch, but more research is needed before the underlying mechanisms 
can be fully understood. Most research into psychological factors and the itch 
sensation is based on cross-sectional studies, and there is a strong need for studies 
with an experimental or prospective design. 
 Next, parts of the biopsychosocial model were examined for their relevance 
to patients with atopic dermatitis and psoriasis (chapter 3.2). A questionnaire study 
was performed to investigate the possible role of self-reported cognitive (worrying), 
behavioral (avoidance behavior), and physiological reactivity factors to chronic 
itch on itch-related measures. All three reactivity systems demonstrated relatively 
uniform and significant correlations with disease severity and were significant 
predictors of itch-related outcomes. 
The final study (chapter 3.3) prospectively investigated parts of the 
biopsychosocial model. The focus of this study was on the influence of daily 
stressors on the change in itch and disease severity in patients with psoriasis. 
The influence of cognitive and behavioral factors on the relationship between 
external stressors and changes in disease severity and itch was also examined. 
For this purpose, a group of patients with psoriasis was followed up for six 
months, using a prospective study design. Each month, patients were asked to 
complete questionnaires on the experience of daily stressors as well as cognitive 
and behavioral reactivity. In addition, clinical and self-reported measures of 
disease severity (PASI) and itch were recorded monthly. Results indicated that the 
experience of daily stressors was associated with an increase in disease severity 
(PASI) and itch four weeks later. As expected, this relationship was only present 
when patients experienced relatively high levels of daily stressors and was not 
present when patients experienced low levels of daily stressors. In addition, results 
showed that an increase in disease outcome was particularly likely for patients who 
had high levels of scratching or worrying at highly stressful periods. 
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The thesis has two main parts. The first part (chapters 2.1, 2.2, and 2.3) describes 
studies that were performed to gain knowledge about the impact of skin diseases 
on patients in general practice. For this purpose, the prevalence of skin diseases 
in general practice and the use of health care facilities by affected general practice 
patients were examined. Studies were also conducted to examine the physical 
symptoms and the psychosocial well-being of patients with skin diseases in general 
practice. The studies desribed in in the second part (chapters 3.1, 3.2, and 3.3) 
were performed to examine biopsychosocial predictors of disease severity and itch 
with emphasis on the influence of daily stressors and psychological factors. The 
findings of the two parts will be separately discussed. This chapter ends with some 
recommendations for future research, clinical implications and overall conclusions.
Part 1. Impact of skin diseases on patients in general practice 
The prevalence, health care use, physical symptoms, and psychosocial well-being of 
general practice patients with skin diseases were studied using data from a general 
practice morbidity registration. Results indicated that skin diseases are common 
among the general population and account for a large proportion (over 12 %) of the 
diseases seen by general practitioners. Patients with a more severe skin disease, 
more symptoms of itch, and a low disease-related quality of life made more frequent 
use of health care services (general practice, specialized care by particularly 
dermatologists and complementary or alternative medicine) than did patients with 
better scores on these measures. Itch and fatigue are common among patients with 
skin diseases in general practice and these patients have a lowered well-being than 
individuals in the general population. 
Use of a Continuous Morbidity Registration
Data from the Continuous Morbidity Registration (CMR) of the Department 
of General Practice of the Radboud University Nijmegen Medical Centre, the 
Netherlands were used to investigate the prevalence of skin disease among the 
general practice population1-3. In addition, questionnaires on the use of health care 
facilities, physical symptoms of itch, pain, and fatigue accompanying skin diseases, 
as well as psychosocial well-being were sent to all patients aged 18 years and older 
who had been registered with commonly encountered skin disease during the 12 
months preceding the study. The CMR was founded in 1971 to study morbidity in 
general practice and records all new episodes of diseases. Consequently, the CMR is 
a diagnosis-based morbidity registration, with diagnoses being recorded according 
to the adapted E-list4, which is compatible with the International Classification 
of Health Problems in Primary Care (ICFPPC-2)5. In the Netherlands, the general 
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practitioner is a gatekeeper of access to specialist medical care, which enables 
the CMR to register referrals to medical specialists and the specialist-reported 
diagnoses as well. The CMR covers a relatively stable practice population of 
approximately 12 000 citizens, who are representative in terms of age and sex of the 
general Dutch population. The use of this systematic continuous registration made 
it possible to clarify the prevalence and impact of skin diseases in a large group of 
patients with many different skin diseases. 
Different morbidity registration systems exist, both nationally and 
internationally, each with its own particular characteristics. International 
differences between systems might be due to differences in health care systems 
between nations. For example, in some countries, such as the Netherlands and the 
United Kingdom, the general practitioner is a gatekeeper of access to specialist 
medical care, while in other countries citizens are free to visit any physician (e.g. 
Germany, Japan, France). This might affect the number of visits made to general 
practitioners and other specialists. Several registration networks exists in the 
Netherlands. These networks differ in their scientific mission, coding of morbidity, 
or registration of diagnosis made by specialists. Due to the differences between 
registration networks, research outcomes may slightly differ between the different 
registration systems. The strengths of the CMR are characterized by the fact that the 
networks was set up specifically for research purposes, supplies feedback on coding 
morbidity by regular meetings of the participating general practitioners, registers 
diagnosis made by specialist, and that the registration is representative of the 
Dutch population6. Although the present findings were in line with previous studies, 
future research should declare whether the present findings can be replicated in 
populations of other national and international registration systems. 
Comparison between general practice and dermatological wards
Most studies of skin diseases have been performed on dermatological wards, 
which means that a large amount of patients with skin diseases who are treated 
by their general practitioner have received little attention. However, there may 
be several differences between patients in general practice and patients seen 
on dermatological wards, for example in disease severity, health care use, 
accompanying symptoms, and psychosocial well-being.  
With regard to health care use, the present study is one of the first that 
investigated health care use among patients with skin diseases in general practice. 
Results showed that many patients with skin disease are primarily treated by general 
practitioners (chapter 2.1). Although these findings correspond with previous 
findings7, another international study found that most people with a skin disease 
among the general population sought care from dermatologists8. This discrepancy 
might be due to the differences in the gatekeeper function of general practitioners 
in different countries, in this case in the Netherlands and France. Though results 
so far provide some preliminary insights into this matter, more research about 
the determinants of health care use is needed for specific skin diseases as well 
as for patients who are treated by general practitioner or by dermatologists on 
dermatological hospital wards. 
Consistent with previous findings9, itch was found to be a dominant 
symptom in the general population (see chapter 2.2). In addition, many general 
practice patients with skin diseases reported fatigue, as has been found among 
patients on dermatological wards10,11. Within this thesis, disease severity was 
measured with the same skin status scale10,12 in both the general practice study and 
the study of patients with psoriasis and atopic dermatitis on a dermatological ward 
(chapter 3.2). As expected, descriptive inspection of these data showed that the 
overall mean score for disease severity was lower among general practice patients 
than among patients with psoriasis and atopic dermatitis on a dermatological ward. 
Although a wide range of disease severity is seen in both settings, this observation 
supports the expectation that the severity of disease is different among patients 
seen on dermatological wards and in general practice, 
In the last study of this first part (chapter 2.3), the psychosocial well-being 
of patients with skin diseases in general practice was compared with that of general 
population. Patients with skin diseases in general practice had a lower psychosocial 
well-being than the general population. As could be expected, the percentage of 
patients at risk of psychosocial impairments, such as a clinical depression was 
lower in the general practice sample than hospital samples13-15, but still concerned 
a considerable number of patients (14.5% in the present general practice sample 
versus 20-50% of the patients seen at dermatological hospital wards). This indicates 
that the impact of skin diseases on psychosocial well-being might be somewhat less 
substantial in general practice than in patients referred to hospital wards. However, 
it has to be noticed that the psychosocial well-being of the general practice patients 
was measured at a random moment in time and not necessarily at the moment 
when patients visited their general practitioner. Consequently, the present findings 
might reflect the overall psychosocial well-being of these patients in daily life. 
Overall, the findings indicated some differences between the disease 
severity and psychosocial well-being of patients with skin diseases seen on 
dermatological wards and general practice. Nevertheless, both patient groups 
report that their disease has a high impact on daily life, and a considerable 
subgroup of patients appear to be at risk of psychosocial impairments.
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Strengths and limitations of the study design 
It is important to recognize that in the study of general practice patients 
(chapters 2.1, 2.2, and 2.3) the questionnaire was administered at a random 
moment and not when patients visited the general practitioner, the latter being 
a moment when the skin disease is probably more active. Therefore, the present 
results are likely to reflect the overall presence and severity of skin diseases in 
daily life and not only the moment when the patient visits a health practitioner. 
In contrast, most previous research was conducted at this latter moment and, 
consequently, data were obtained for a rather limited group of patients. 
Several limitations of the study design of this first part of the thesis needs 
to be considered. Although the CMR contains data from a relatively stable practice 
population of approximately 12 000 citizens, the subgroups of patients with specific 
skin diseases were relatively small. This made it impossible to draw conclusions 
about the relationship between physical and psychological well-being and other 
disease-related factors for individual skin diseases. In addition, health care use 
by subgroups of patients could not be analyzed. More research in larger samples 
is necessary to analyze possible differences between subgroups of patients with 
different skin diseases. For example, the results described in chapter 2.2 indicate 
that there may be differences in the physical symptoms accompanying different 
skin diseases. Although overall relatively few patients reported experiencing 
pain, a considerable amount of patients with specific diagnoses e.g. corns, 
contact dermatitis and pruritus patients did report pain. There were no significant 
demographic differences between the responders and non-responders with regard 
to gender and educational level, but patients who returned the questionnaire were 
significantly younger than the patients who did not. To some extent, this difference 
does limit the generalizability of our findings. Finally, it has to be kept in mind that 
the CMR is a diagnosis-based registration system. Consequently, the study of the 
use of health care facilities relies on retrospective, self-reported information about 
the number of contacts with health care provides. Although the presented results 
are in line with previous results on this subject7, it cannot be excluded that the 
retrospective and self-reported nature of the data might have influenced the results 
on the use of health care facilities as described in chapter 2.1. Future research on 
this subject should indicate the generizability of the present findings on health  
care use.
Part 2. Biopsychosocial predictors of itch and disease severity
The present thesis proposes the influence of psychological factors in the disease 
outcome of patients with skin diseases. Therefore, a stress-vulnerability model 
was elaborated for patients with skin diseases (see Introduction, figure 2). Stress-
vulnerability models are based on the hypothesis that internal vulnerability factors 
(e.g. personality) and external environmental factors (e.g. stressors) affect disease 
outcome. Additionally, specific psychological factors of individual recativity factors 
might mediate or moderate this relationship. Within this thesis, several aspects 
of this model were studied in patients with skin diseases, with particular attention 
being paid to the effects of daily stressors and cognitive and behavioral reactivity 
factors. 
Influence of daily stressors
The relationship between stressors and skin diseases has received increasing 
attention over the years. For many skin disease, the influence of stressors on the 
course of disease severity is controversial or insufficiently examined. For some skin 
disease, such as psoriasis and atopic dermatitis, some preliminary evidence exists 
for a relationship between stressors and the course of disease severity16. However, 
there have been few prospective studies investigating the relationship between 
stressors and the course of these skin diseases. While the physiological stress 
response involves alterations in the hypothalamic-pituitary-adrenal (HPA) axis that 
in turn affect parameters of the immune system17, skin diseases with an underlying 
immunological pathology, such as psoriasis, might be susceptible to the influence 
of stressors. Stressors can be divided in several types of stressors including major 
life events (e.g. the death of a spouse) and daily stressors (e.g. running late for an 
appointment or losing your keys). Although many studies have focused on major 
life events and health, daily stressors have generally been found to be substantially 
better predictors of health outcome than major life events18,19. 
To investigate whether daily stressors influence the outcome of psoriasis, 
a prospective study with repeated measurements over time was conducted, as 
described in chapter 3.3. With this design, it could be determined whether daily 
stressors precede changes in the severity of the disease and the physical symptom 
of itch. As expected, at moments when patients report a heightened level of daily 
stressors, there was a significant relationship between daily stressors and an 
increase in both disease severity and itch four weeks later. The findings of our study 
are consistent with those of other cross-sectional studies of patients with psoriasis. 
For example, it has been reported that patients with psoriasis who experience more 
life events have a higher disease severity and more itch compared with patients who 
experience fewer life events20-24. Furthermore, our results are consistent with those 
of prospective studies focusing on the relationship between stressors and disease 
in other chronic conditions. For example, significant prospective relationships 
134 135
G
en
er
al
 d
is
cu
ss
io
n
C
h
ap
te
r 
5
between daily stressors and an increase in disease severity have been reported 
in patients with atopic dermatitis25,26. Similar prospective relationships between 
stressors and disease severity have been reported for other chronic inflammatory 
disease such as rheumatoid arthritis27-29. It should be noted, however, that in the 
present thesis, a relationship between daily stressors and changes in disease 
outcome was found only at moments when patients reported experiencing a high 
level of daily stressors, which suggests that the relationship between daily stressors 
and changes in disease outcome is only present when daily stressors reach certain 
level. 
While particularly daily stressors have been described as predictors of 
health outcome, in the thesis the Everyday Problem Check List (EPCL)19,30 was used 
to study daily stressors. Daily stressors can be further divided in several categories 
and the question arises whether these categories have different relationships with 
health outcome. Besides daily environmental stressors, the EPCL contains items 
on daily interpersonal stressors. For skin diseases, preliminary evidence exists that 
interpersonal stressors influence physiological factors in patients with skin diseases, 
suggesting that interpersonal stressors might indeed evoke a stress response31-34. 
It has been argued for other chronic inflammatory diseases that particularly these 
interpersonal stressors enhance physiological responses and disease outcome29;35, 
and thus it would be interesting to investigate these interpersonal stressors in 
future research. In addition to more objective assessments of the occurrence 
of daily stressors, it has also been suggested that the emphasis in the relation 
between stressors and health outcome should be on the individual’s perceived 
stress, independent of specific stressors. In patients with skin diseases, perceived 
stress has not been shown to be associated with disease severity36. Previously, the 
measure of perceived stress has been found to show weak correlations with other 
measures of stressors37. A specific concept relevant to patients with skin diseases is 
stigmatization (e.g. the experience that others stare, feel uncomfortable touching 
patients, making annoying comments about their skin, or avoid contact at all). This 
concept might reflect one component of perceived stress. Both perceived stress 
and stigmatization can be considered as individual reactivity factors that might 
reflect aspects of personality or mood state, rather than the occurrence of external 
stressors. Stigmatization has been associated with higher levels of itch and disease 
severity in patients with atopic dermatitis and psoriasis12,38 as well as higher levels 
of anxiety and a more negative mood12. Further research should show whether 
our findings concerning the experience of general daily stressors in relation to 
the course of disease outcome can be generalized for the other categories of daily 
stressors. Moreover, future research should identify the similarities and differences 
between the different constructs of stressors and their relationship with other 
psychological and physiological factors and disease outcome.
Psychological mediating or moderating factors
According to the stress-vulnerability model (see General Introduction, figure 2), the 
relationship between external stressors and disease outcome may be influenced by 
several psychological (cognitive and behavioral) factors. In this thesis, a particular 
focus was on the influence of the cognitive factor “worrying”, and the behavioral 
factors “scratching” and “avoidance behavior” .
Cognitive reactivity factor of worrying. 
Perseverative worrying is a common response to disease or stressful events and has 
been reported to prolong stress-related affective and physiological activation (e.g. 
of the endocrine and immune systems)39. Consequently, worrying could influence 
physical well-being through several psychological and physiological pathways. 
Previous studies in patients with chronic skin diseases showed that a considerable 
number of these patients experience high levels of worrying thoughts40,41. 
Furthermore, high levels of worrying have been shown to significantly slow the 
treatment outcome of PUVA photochemotherapy in patients with psoriasis41. 
However, explicit knowledge about the relationship between worrying and indices 
of disease outcome (e.g. disease severity or itch) in patients with psoriasis has 
been relatively limited. The studies described in this thesis showed worrying to 
be significantly related with itch (chapter 3.2) and to predict an increase in itch 
four weeks later (chapter 3.3). Furthermore, worrying moderated the relationship 
between daily stressors and the change in itch after four weeks among patients with 
psoriasis. An increase in itch was particularly present in patients with high levels of 
daily stressors and high levels of worrying (chapter 3.3). The question arises why 
worrying was predominantly associated with the self-reported measure of itch and 
not with the clinical measure of disease severity (PASI). One explanation might 
be that the instruments used to determine worrying specifically asked about the 
patient’s reactivity to itch. Consequently, more research is necessary to determine 
the underlying mechanisms of the relation between worrying and disease outcome 
in patients with skin diseases. 
Behavioral reactivity factors of avoidance behavior and scratching.
Enduring patterns of avoidance behavior have been related to higher levels of 
itch, more scratching, and higher levels of disease-related disability in patients 
with psoriasis42-44. The acute effects of the symptoms of skin diseases, such as itch, 
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predominantly trigger physical activity, and in particular scratching. The long-term 
behavioral response is to withdraw from activities or to avoidance daily activities in 
order to prevent an exacerbation of symptoms. In the study described in chapter 3.2, 
avoidance behavior was found to have a significant, positive association with itch as 
well as itch-related factors of scratching and psychosocial well-being. However, after 
controlling for other factors such as demographic variables and disease severity, 
the relation with itch and scratching became weaker, and avoidance behavior 
significantly predicted psychosocial well-being only. Similarly, avoidance behavior 
was not related to changes in physical disease outcome in chapter 3.3. The follow-
up period of four weeks might have been too short to assess long-term effects on 
physical outcome. Among other chronic diseases where avoidance behavior is an 
acute response to the disease symptoms, avoidance behavior is related to long-
term outcomes in particular. For example, in patients with rheumatoid arthritis, 
avoidance behavior predicts disease activity after one, three and even five years45. 
Future studies should reveal whether avoidance behavior is a long-term predictor of 
disease severity and itch in patients with skin diseases. 
Scratching is an important behavioral factor within the stress-vulnerability 
model of skin diseases accompanied by itch. Scratching is even a main part of the 
definition of itch as an unpleasant sensation that evokes the desire to scratch46. 
Although the immediate reinforcement of scratching is the reduction of itch, 
patients with enduring itch due to chronic skin diseases persist in their scratching 
behavior, even till the skin bleeds. The reinforcement of scratching enhances 
a vicious itch-scratch-itch circle, and this vicious circle is suggested to have an 
important role in the maintenance and exacerbation of chronic skin diseases. The 
vicious itch-scratch-itch circle has been related to several psychological factors, 
such as higher levels of worrying12,47,48. Furthermore, scratching induces several 
physiological responses, such as altered endocrine and immune parameters49-
51, which might affect the outcome of skin diseases. In chapter 3.2 of this thesis, 
scratching was indeed found to be related to psychological factors of worrying, 
avoidance behavior, and self-reported physiological reactivity. Furthermore, 
scratching significantly predicted an increase in both disease severity and itch after 
four week (chapter 3.3). 
Physiological reactivity 
With regard to the physiological factors related to the stress-vulnerability 
model (see General Introduction, figure 2), the autonomic reactivity (e.g. sweating) 
was examined by means of a self-reported measures within chapter 3.2. Autonomic 
physiological reactivity when exposed to a stressor is part of the natural response 
to stressors. For patients with chronic pain, this reactivity factor has been shown to 
predict an increase in forthcoming pain52. This thesis showed self-reported autonomic 
physiological reactivity also to be significantly related to itch (chapter 3.2). The 
question arises whether and to what extent this self-reported measure represents 
physiological reactivity. As in chronic pain patients, this measure is possibly affected 
by attentional or interpretational processes such as hypervigilance or represent 
a heightened physiological arousal52,53. Although the results indicate a role of 
autonomous reactivity in disease outcome of patients with skin diseases,  
more research is necessary to examine the influence of physiological factors. 
Besides autonomous factors, endocrine and immune factors might also be 
involved in the relation between psychological factors and disease outcome. For 
patients with skin disease, changes in cortisol (an important glucocorticoid) after 
stressor exposure have been observed in patients with psoriasis54-56. These changes 
have even been reported to differ from healthy controls54,55. Cortisol has also been 
described to differ between moments of psoriasis exacerbations and moments of 
psoriasis remissions, indicating a possible influence of cortisol on disease severity57. 
An altered endocrine and related immune response to stressors may modify the 
regulatory mechanism of the HPA axis, leading to an alteration in pro-inflammatory 
cytokines and an exacerbation of disease severity. However, very few studies have 
examined the influence of cortisol or immune markers on disease outcome in  
patients with skin diseases and prospective studies examining predictors of disease 
outcome including cortisol and immune measures are lacking. 
Strengths and limitations of the study design 
Prospective research with repeated measurements over time can provide an insight 
into the nature of the relationship between stressors, individual reactivity factors, 
and measures of disease outcome. Within this thesis, the main effects of individual 
reactivity factors of worrying, avoidance behavior, and physiological reactivity on 
chronic itch were also examined by means of a cross-sectional study design (chapter 
3.2). From this study, no inferences could be made about causal relationships between 
itch and reactivity factors of itch. Consequently, a prospective study design was used 
in the study described in chapter 3.3 in order to study the relation between daily 
stressors, individual recativity factors, and changes in disease outcome over time. 
There are several limitations with respect to the generalizability of the results. 
First, the study sample in the last chapter of the thesis (chapter 3.3) consisted for 
more than half of the study sample of older males. Furthermore, in order to control 
for medication effects, only patients on a stable (over last three months) systemic 
medication regimen were included in the study. This might explain the relatively 
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moderate disease severity observed in these patients. Moreover, during the study 
patients were excluded if their treatment regimen was changed, which could have 
resulted in less variability in disease severity within and between subjects. It cannot 
be excluded that the design of the study with repeated self-monitoring assessments 
might have positively affected patients’ behavior, such as compliance with the 
application of topical medication. Furthermore, while a wide range of possibly 
confounding demographic variables, the use of medication, and comorbidity 
was assessed, it cannot be excluded that additional factors (e.g. social support) 
might also have contributed to the relationship between daily stressors, individual 
reactivity factors and changes in disease outcome. Next, the follow-up period of 
six months might not be appropriate to observe a period with high levels of daily 
stressors in all participants. Six months is a relatively short period and it cannot 
be guaranteed that all subjects will experience high levels of daily stressors in this 
period. Nevertheless, when the month (out of six months) participants reported 
the highest amount of daily stressors was selected, daily stressors were found to 
correlate with the change in disease severity and itch four weeks later. Finally, 
variables were measures monthly, which is consistent with the notion that over 
60% of the patients with psoriasis retrospectively report to experiencing stressful 
life events in the month before disease exacerbation20,22,24. Nevertheless, this time 
interval might not be optimal for detecting a relationship between daily stressors 
and changes in disease outcome. For example, in patients with atopic dermatitis 
external stressors caused an increase in self-reported disease severity and itch after 
one day 25;26. Further studies with shorter (daily) intervals should demonstrate the 
optimal interval for detecting a relationship between external stressors and changes 
in disease outcome in patients with psoriasis. 
Future research 
The first part of this thesis (chapters 2.1, 2.2, and 2.3) describes the prevalence, 
health care use, accompanying physical symptoms, and psychosocial well-being of 
patients with skin diseases in general practice. Findings underline the notion that 
the prevalence of specific skin diseases is not stable over time, which emphasizes 
the importance of ongoing monitoring of the prevalence of these diseases. 
Additionally, the importance of using valid measures in research on health care 
utilizations was emphasized. Although this thesis provides some information about 
the use of health care facilities by patients with skin diseases, future research should 
support our findings for separate categories of skin diseases. Moreover, information 
is needed about the underlying mechanisms explaining why and when patients with 
particular skin diseases use different health care facilities. 
The present studies show that patients with skin diseases report not only 
itch but also substantial levels of fatigue and to a lesser extend pain (chapter 
2.2). So far, research has rarely focused on these aspects of skin diseases. Fatigue 
appears to be a common symptom among patients with chronic diseases. For 
example, patients with multiple sclerosis, rheumatologic conditions, neuromuscular 
disorders, and cancer, are known to report high levels of fatigue 58-61. Moreover, 
fatigue appears to be a common symptom among patients visiting their general 
practitioners62,63. For patients with skin diseases, little is known about the factors 
associated with fatigue and its role in measures of disease outcome. Although 
fatigue was not a main outcome within this thesis, fatigue among patients with 
skin diseases was related to both disease specific factors (such as disease severity) 
and psychological well-being (chapter 2.2.). Further prospective research is 
needed to determine whether fatigue is merely a result of skin conditions, whether 
psychosocial predictors affect fatigue in skin diseases, or whether fatigue is a 
predictor of disease outcome in skin diseases.
In general, gender has been regarded as a possible determinant in 
persons’ individual perception of health64-66. Although the influence of gender 
was not the main focus of the studies presented within this thesis, findings of 
chapter 2.2 and 2.3 are in line with the notion that women experience more health 
complaints. In these studies low, but significant correlations indicating that women 
experience more pain and fatigue and a have a lower psychosocial well-being 
were found. No such gender differences were found for itch, which is particularly 
a physical symptom related to skin diseases. Moreover, no gender differences 
were found regarding the use of disease-related health care facilities (chapter 
2.1). Although there might be a general tendency for women to experience more 
health complaints, the underlying mechanism are so far unknown. Moreover, in the 
present thesis there were no clear gender differences in disease specific symptoms 
and disease-related health care use. It would be interesting for future research 
to more specifically examine the influence of gender with regard to psychosocial 
factors and disease-related health complaints. 
In the second part of this thesis (chapters 3.1, 3.2, and 3.3) a stress-
vulnerability model for disease outcome in patients with skin diseases is proposed. 
After a general review, specifically the influence of daily stressors and individual 
reactivity factors of cognitive and behavioral nature on disease outcome in patients 
with psoriasis was examined. Future research should determine whether the 
influence of daily stressors on the outcome of psoriasis also affects the outcome of 
other skin diseases. Furthermore, the generalizability of findings to other settings 
(e.g. the general practice) should be examined. Although based on the wide range 
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of patients with psoriasis seen by general practitioners the same predictors are likely 
to apply among this population, this should receive further attention. Additionally, 
while daily stressors as measured within this thesis are but one operationalization 
of stressors, future research should investigate possible differences or similarities 
between the effects of different types of stressors on changes in disease outcome. 
Additionally, although the individual reactivity facors of worrying and 
avoidance behavior were shown to be important in skin diseases, several other 
factors should be considered. For example, social factors (such as perceived support 
and social network) could have an important influence on disease outcome in 
patients with skin diseases (chapter 3.1). Furthermore, cognitive factors such as 
acceptance or helplessness, have been related to disease outcome in patients with 
skin diseases and need more attention10,12,38,67.
Finally, it is important to examine the relationships between daily stressors 
and psychophysiological factors in an experimental design, in order to clarify 
causal relationships. For example, the question arises whether the self-reported 
autonomic physiological reactivity as used in this thesis can be validated within an 
experimental design where heart rate, skin conductance and blood pressure are 
measured after exposure to experimentally evoked stressors. Furthermore, although 
within chapter 3.3 clinical physiological alterations of disease severity (PASI) and 
itch were demonstrated four weeks after patients experienced high levels of daily 
stressors, the actual temporal relationship between the experience of stressors and 
physiological alterations remains unknown. An experimental design would make 
it possible to gather information about the course of physiological stress reactivity 
after exposure to stressors, providing a unique opportunity to evaluate the temporal 
relationship between stressors and physiological alterations. Additionally, in order 
to control for the influence of patients’ medication regimens, patients with stable 
medication regimen were selected for the prospective study in chapter 3.3, this 
might have resulted in a study sample with a somewhat lower and extremely stable 
disease severity. Experimental study designs might overcome such limitations. The 
combined results of prospective daily life studies and experimental studies should 
provide further insights into the underlying mechanism of stress reactivity.
Clinical implications
Overall, the results of this thesis show the importance of psychological factors 
on disease outcome among patients with skin diseases. Even in general practice 
a substantial proportion of patients with skin diseases might be at risk of severe 
psychological impairments such as a clinical depression. Previous research showed 
that these impairments are hard to recognize by health care providers68. For this 
reason, it would seem appropriate to develop screening instruments for general 
practice. Although several attempts for the developments of such questionnaires 
has been made69, the implementation of this procedure is generally lacking. 
 Besides a lowered psychological well-being, psychological factors 
may affect the outcome of patients with skin diseases who are treated on a 
dermatological ward. Regular monitoring of both the experience of daily stressors 
and individual-reactivity factors of particularly scratching and worrying might alert 
dermatologists when such effects might occur. Accordingly, treatment regime might 
be directed to the possible effects of stressors and related cognitive and behavioral 
factors on disease outcome. 
Several studies have shown a positive effect of psychological treatment 
focusing on stress management, relaxation or cognitive-behavioral factors on 
disease outcome of patients with skin diseases70,71. The findings reported in this 
thesis suggest that these cognitive-behavioral treatments should focus on the 
individual factors of worrying and scratching in the treatment of skin diseases. 
However, cognitive-behavioral treatments for skin diseases are not yet generally 
available and so far only few are specialized in the treatment of patients with 
skin diseases. The present thesis clearly supports the possible additional value of 
psychological treatment for the disease outcome of e.g. patients with psoriasis, 
particularly when they are focused on specific risk factors of particularly stressors 
and individual reactivity factors of worrying and scratching.
Conclusions
In line with the summary and general discussion, the main conclusions of this thesis 
can be summarized as follows:
•		 Skin	diseases	are	common	among	the	general	population	and	account	for	a	
large proportion of all diseases seen by general practitioners.
•		 Itch	and	fatigue	are	frequently	experienced	by	patients	with	skin	diseases;	
over 50% of all patients with a skin disease report these symptoms.
•		 Patients	with	skin	disease	seen	in	general	practice	have	a	lowered	
psychosocial well-being when compared with the general population.
•		 Daily	stressors	affect	both	disease	severity	and	itch	four	weeks	later	in	
patients with psoriasis, but only at times when patients experience high 
levels of daily stressors.
•		 Particularly	patients	with	high	levels	of	scratching	and	worrying	are	
susceptible to the influence of daily stressors on the course of disease 
outcome.
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Inleiding
Hoewel huidaandoeningen veel voorkomen onder de algemene bevolking, is hier 
toe nu nog weinig wetenschappelijke aandacht voor geweest. Onderzoek heeft 
zich tot nu toe voornamelijk gericht op de meest voorkomende huidaandoeningen 
op het dermatologisch spreekuur in ziekenhuizen, zoals psoriasis en atopisch 
eczeem. Hierdoor blijven minder vaak voorkomende huidaandoeningen en 
huidaandoeningen die niet worden behandeld door een dermatoloog buiten 
beschouwing. Kennis over de dermatologische ziekenhuis populatie is echter 
niet vanzelfsprekend van toepassing op andere populaties zoals bijvoorbeeld 
de huisartspraktijk. Er is onderzoek nodig in beide settings, zowel binnen 
ziekenhuissetting als die van de huisartspraktijk. Ook is weinig bekend over 
de gevolgen van huidaandoeningen voor het dagelijks leven en welke factoren 
hierop mogelijk van invloed zijn. Met name naar de invloed van een breed scala 
biopsychosociale factoren bij chronische huidaandoeningen is nog onvoldoende 
onderzoek verricht. Zo geeft bijvoorbeeld een groot aantal patiënten met chronische 
huidaandoeningen, zoals psoriasis, aan dat psychologische stressfactoren van 
invloed zijn op het beloop van hun huidaandoening. Deze relatie is echter tot op 
heden nog onvoldoende wetenschappelijk onderzocht. 
In dit proefschrift worden huidaandoeningen zowel in de huisartspraktijk 
als in een ziekenhuissetting onderzocht. In het eerste deel van dit proefschrift wordt 
binnen de huisartspraktijk de invloed van huidaandoeningen op het dagelijks leven 
onderzocht (hoofdstukken 2.1, 2.2 en 2.3). Vervolgens komt in het tweede deel 
van dit proefschrift de invloed van biopsychosociale factoren op de verergering en 
instandhouding van huidaandoeningen zoals gezien op dermatologie afdelingen 
aan de orde. Na een algemeen overzicht (hoofdstuk 3.1), wordt dit onderwerp 
verder onderzocht bij patiënten met chronische huidaandoeningen, zoals eczeem 
en/of psoriasis (hoofdstukken 3.2 en 3.3).
Invloed van huidaandoeningen in de algemene bevolking
Sinds de eerste morbiditeitsanalyses is bekend dat huidaandoeningen een 
substantieel aandeel vormen van alle aandoeningen die door huisartsen in 
Nederland gezien worden (± 10%). De beschreven stijging in de prevalentie van 
bepaalde huidaandoeningen (met name atopisch eczeem en huidtumoren) geeft 
aan dat het belangrijk is het voorkomen van huidaandoeningen goed in kaart te 
brengen. Naast informatie over het voorkomen van een bepaalde aandoening is 
kennis van het zorggebruik van mensen met deze aandoening belangrijk om een 
indruk te krijgen van de impact die een aandoening heeft op de samenleving. Zo 
kan er op basis van informatie over de prevalentie van een aandoening bijvoorbeeld 
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een schatting gemaakt worden van kans dat iemand een bepaalde aandoening 
heeft. Informatie over het zorggebruik en de kenmerken van hen die zorg 
zoeken kan een indruk geven over de economische impact van een ziekte op de 
samenleving. 
Algemene definities van gezondheid en maten voor ziekte-uitkomsten 
omvatten verschillende relevante aspecten zoals ernst van de aandoening, 
lichamelijke klachten en psychosociaal welbevinden. Deze drie aspecten dragen 
bij tot de impact die een aandoening heeft op het dagelijks leven van de patiënt. 
Informatie over deze aspecten is tevens van belang voor de behandeling van 
huidaandoeningen. Zo kan dergelijke informatie helpen bij een vroege herkenning 
of adequate behandeling van een aandoening. 
Figuur 1: Ziekte-uitkomsten aan de hand van algemene gezondheidsdefinities
Jeuk is een veelvoorkomend symptoom bij veel huidaandoeningen. Kennis 
omtrent andere lichamelijke symptomen bij huidaandoeningen is nog schaars, 
hoewel symptomen als pijn en vermoeidheid wel beschreven zijn bij patiënten 
die door dermatologen behandeld worden. Uit onderzoek weten we dat bij de 
dermatologische populatie het psychosociaal welbevinden verlaagd is ten opzichte 
van de algemene bevolking. De invloed van huidaandoeningen zoals die gezien 
worden in de huisartspraktijk op het psychosociaal welbevinden is echter nog 
nauwelijks onderzocht.
Biopsychosociale voorspellers van ziekte-aspecten in patiënten met een 
huidaandoening
Onderzoek bij chronische lichamelijke aandoeningen laat zien dat 
psychologische factoren (bijvoorbeeld persoonlijkheid of externe stressoren) het 
ziektebeloop kunnen beïnvloeden. Hoewel deze relatie bij andere chronische 
aandoeningen veel aandacht heeft gekregen, is er nog weinig bekend over 
de psychologische factoren die mogelijk een rol spelen in de verergering 
en instandhouding van huidaandoeningen. Wel is er reeds aangetoond dat 
psychologische interventies een aanvullende en positieve bijdrage kunnen leveren 
aan de behandeling van huidaandoeningen. De invloed van psychologische factoren 
op huidaandoeningen onderstreept het belang van een biopsychosociale visie op 
deze aandoeningen. 
In het tweede deel van dit proefschrift wordt onderzocht welke 
biopsychosociale factoren een rol spelen bij de verergering en instandhouding 
van huidaandoeningen. Biopsychosociale factoren kunnen het best weergegeven 
worden in een diathese-stress model dat gebaseerd is op de aanname dat 
interne kwetsbaarheidfactoren (zoals bijvoorbeeld persoonlijkheid) en externe 
omgevingsfactoren (bijvoorbeeld stressoren) de ziekte kunnen beïnvloeden. 
Deze relatie kan tevens beïnvloed worden door ander psychologische factoren als 
sociale steun, cognitieve factoren als bijvoorbeeld piekeren en gedragsfactoren 
als vermijdingsgedrag of specifiek voor jeuk veelvuldig krabgedrag (zie figuur 2). 
Om te onderzoeken of factoren uit het biopsychosociale model, zoals stressoren 
invloed kunnen hebben op de ziekte-uitkomst bij huidaandoeningen zijn vooral 
prospectieve studies aangewezen. Echter, dit soort studies zijn tot op heden schaars 
voor patiënten met huidaandoeningen.
Figuur 2: Biopsychosociaal model van chronische huidaandoeningen
Samenvatting van de onderzoeksbevindingen
Invloed van huidaandoeningen in de algemene bevolking
In het eerste deel van dit proefschrift worden gegevens gebruikt van de Continue 
Morbiditeits Registratie (CMR) van de afdeling Huisartsgeneeskunde van het UMC 
St Radboud. Dit registratie systeem houdt sinds de jaren zeventig alle aandoeningen 
bij die gepresenteerd worden aan de betrokken huisartsen. Op dit moment zijn er 
Interne factoren:
•	Persoonlijkheid	
Psychologische 
mediërende of  
moderende factoren:
 Cognitieve factoren b.v.
	 	 •	Piekeren
 Gerdagsfactors b.v.
	 	 •	Krabgedrag
	 	 •	Vermijdingsgedrag
 Sociale factoren b.v.
	 	 •	Sociale	steun
	 	 •	Sociaal	netwerk
Physiologische  
factoren:
	 •	Autonoom
	 •	Endocrien
	 •	Immunologisch
Ziekte- 
uitkomst
Externe factoren:
•	Stressoren
Ziekte- uitkomsten
	 •	Ernst	van	de	aandoening
	 •	Lichamelijke	symptomen
	 •	Psychologisch	en	sociaal	welbevinden
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vier huisartspraktijken en 11 huisartsen betrokken bij de registratie. De registratie 
omvat een relatief stabiele populatie van ongeveer 12.000 personen, die wat betreft 
leeftijd en geslacht representatief zijn voor de Nederlandse bevolking. Naast het 
in kaart brengen van de huidige prevalentie van huidaandoeningen werd bij deze 
populatie middels vragenlijsten het zorggebruik, de lichamelijke symptomen en 
het psychosociaal welbevinden van patiënten met een huidaandoening onderzocht. 
Resultaten lieten zien dat huidaandoeningen 12.4% uitmaken van alle aan de 
huisarts gepresenteerde aandoeningen (hoofdstuk 2.1). Zoals verwacht werden 
er met name hoge prevalenties gevonden voor bijvoorbeeld psoriasis en atopisch 
eczeem. Inventarisatie van het zorggebruik liet zien dat 80% van alle patiënten 
met een huidaandoening in het afgelopen jaar contact had met hun huisarts voor 
deze aandoening en dat 65% hiervoor enkel door de huisarts behandeld werd 
(hoofdstuk 2.1). Patiënten met een relatief ernstigere aandoening, meer jeuk en een 
lagere kwaliteit van leven gingen vaker naar de huisarts, specialist of alternatieve 
zorgverlener.
 In hoofdstuk 2.2 wordt het voorkomen van lichamelijke symptomen 
bij patiënten met een huidaandoeningen in de huisartspraktijk onderzocht. De 
resultaten geven aan dat het merendeel van alle mensen met een huidaandoening 
jeuk, pijn en/of vermoeidheid ervaart. Meer dan de helft van alle patiënten geeft aan 
jeuk of vermoeidheid te ervaren, 25% hiervan ervaart deze symptomen in relatief 
ernstige mate. Pijn komt minder vaak voor bij patiënten met een huidaandoening 
en bleek over het algemeen ook minder hevig in intensiteit. De lichamelijke 
symptomen waren het sterkst gerelateerd aan de ernst van de huidaandoening en 
kwaliteit van leven. 
 In het laatste hoofdstuk van dit deel (hoofdstuk 2.3) wordt middels een 
vragenlijst het psychosociale welbevinden van patiënten met een huidaandoening 
in de huisartspraktijk onderzocht en vergeleken met het welbevinden van de 
algemene Nederlandse bevolking. Naar voren kwam dat patiënten met een 
huidaandoening in de huisartspraktijk een lager psychosociaal welbevinden 
hebben dan de algemene bevolking. Vooral patiënten met een ernstigere en langer 
durende huidaandoening en patiënten met meer lichamelijke symptomen of 
andere, comorbide aandoeningen bleken een lager welbevinden te rapporteren. 
Een aanzienlijk aantal patiënten (zo´n 15%) bleek een risicoprofiel te hebben voor 
het ontwikkelen van psychologische beperkingen, zoals bijvoorbeeld een klinische 
depressie.
Biopsychosociale voorspellers van ziekte-aspecten in patiënten met een 
huidaandoening
In het tweede deel van dit proefschrift worden biopsychosociale voorspellers van 
ziekte-aspecten onderzocht. In hoofdstuk 3.1 wordt allereerst een overzicht gegeven 
van reeds bestaande studies omtrent de biopsychosociale voorspellers van jeuk 
bij patiënten met chronische huidaandoeningen. Hierbij werd met name gekeken 
naar de effecten van persoonlijkheid, externe stressoren, cognitieve, gedragsmatige 
en sociale factoren. Tevens wordt de mogelijke rol van een aantal fysiologische 
factoren beschreven. Het hoofdstuk laat de meerwaarde van een biopsychosociaal 
model voor jeuk bij chronische huidaandoeningen zien. Echter, aangezien het 
merendeel van de beschreven studies gebaseerd waren op cross-sectionele designs 
werd geconcludeerd dat verder onderzoek met een experimentele of prospectieve 
methodiek noodzakelijk is. 
 In hoofdstuk 3.2 worden onderdelen van het biopsychosociale model 
onderzocht bij patiënten met psoriasis en atopisch eczeem. In een cross-sectionele 
studie werd de relatie tussen jeuk en cognitieve (piekeren), gedragsmatige 
(vermijden) en fysiologische reactiviteit op jeuk onderzocht. Zowel cognitieve, 
gedragsmatige als fysiologische reactiviteit waren significant gerelateerd aan de 
ernst van de huidaandoening en jeuk.
 In de laatste studie (hoofdstuk 3.3) wordt een ander deel van het 
biopsychosociale model prospectief onderzocht. In deze studie werden patiënten 
met psoriasis gedurende zes maanden gevolgd om de relatie tussen externe, 
dagelijkse stressoren en veranderingen in jeuk en ernst van de aandoening 
in kaart te kunnen brengen. Daarbij werd tevens de invloed van cognitieve en 
gedragsmatige factoren op deze relatie onderzocht. Het meemaken van een hoge 
mate van dagelijkse stressoren bleek samen te hangen met een verergering van 
de klinische ernst van de psoriasis en een toename van jeuk. Zoals verwacht bleek 
deze relatie enkel te bestaan op momenten dat patiënten aangaven een hoge mate 
van dagelijkse stressoren te ervaren. Daarnaast bleek dat vooral patiënten met een 
hoge mate van krabgedrag en patiënten die veel piekeren ontvankelijk zijn voor de 
invloed van stressoren op hun huidaandoening.
 
Conclusies
De belangrijkste conclusies van het onderzoek zoals beschreven in dit proefschrift 
kunnen als volgt worden samengevat:
	 •		 	Huidaandoeningen	komen	veel	voor	onder	de	algemene	bevolking	en		
vormen een substantieel aandeel van alle aandoening die gezien worden 
door de Nederlandse huisartsen.
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	 •		 	De	lichamelijke	symptomen	van	jeuk	en	vermoeidheid	komen	veel	voor	bij	
mensen met een huidaandoening; meer dan 50% van de patiënten geven 
aan deze symptomen te ervaren. 
	 •		 	Patiënten	die	zich	met	een	huidaandoening	presenteren	in	de	
huisartspraktijk hebben een lager psychosociaal welbevinden dan de 
algemene bevolking. 
	 •		 	Dagelijkse	stressoren	beïnvloeden	het	ziektebeloop	(zowel	ernst	van	
de aandoening als jeuk) van patiënten met psoriasis, maar alleen op 
momenten dat patiënten een hoge mate van dagelijkse stressoren ervaren. 
	 •		 	Vooral	patiënten	met	een	hoge	mate	van	krabgedrag	en	patiënten	die	
veelvuldig piekeren zijn ontvankelijk voor de invloed van dagelijks 
stressoren op hun huidaandoening. 
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Voor de uitvoering en de uiteindelijke afronding van dit proefschrift ben ik vele 
mensen mijn dank verschuldigd.
Allereerst natuurlijk de patiënten die aan alle onderzoeken hebben meegedaan.  
Het invullen van alle gebruikte vragenlijsten in dit proefschrift heeft bij elkaar vele 
uren van uw tijd in beslag genomen, mijn dank hiervoor. Alleen door uw deelname 
is dit proefschrift mogelijk geworden. 
Mijn dank gaat tevens uit naar mijn promotoren. 
Floor, ik ben je zeer dankbaar voor al je goede suggesties en het geduld waarmee je 
keer op keer bereid was me verder op weg te helpen en uitleg te geven, met name 
op statistisch gebied.  
Peter, jouw eeuwige positieve instelling en commentaar met hier en daar 
een kritische kanttekening  waren voor mij altijd weer een stimulus om vol 
enthousiasme door te gaan. 
Chris, onder jouw hoede heb ik me wegwijs gemaakt in de wereld van de 
huisartsgeneeskunde. Dank voor de vele praktische en inhoudelijke tips.
Ik ben ervan overtuigd dat zonder de goede, soms bijna dagelijkse begeleiding 
van mijn co-promotor Andrea Evers dit proefschrift nooit tot stand had kunnen 
komen. Andrea, bedankt dat ik de afgelopen jaren een kijkje in jouw keuken van 
wetenschappelijk onderzoek heb mogen nemen, ik heb er erg veel van geleerd. 
Dank voor de vele tijd die je genomen hebt om me iedere keer weer praktisch, 
inhoudelijk en soms ook emotioneel op koers te houden. 
Een proefschrift schrijven doe je niet eenzaam en alleen vanuit een ivoren torentje. 
Voor het verzamelen van alle onderzoeksgegevens gaat mijn dank uit naar vele 
mensen. 
Allereerst: Ria te Winkel-Slotboom. Zonder jouw kennis en bereidheid om altijd 
bij te springen indien nodig, was de data verzameling en data invoer van bijna alle 
studies die in dit proefschrift  beschreven zijn niet zo vlekkeloos verlopen.  
Dit gebeurde ook nog eens op een hele leuke en gezellige manier. Dank voor al onze 
gesprekken. En als laatste, dank aan je twee zonen. Uren hebben zij besteed aan het 
invoeren van allerlei gegevens, ook gegevens die niet zo gemakkelijk en leuk waren 
om in te voeren. Soms was ik bang jullie gezin tot wanhoop te drijven, gelukkig was 
dit niet het geval. 
166 167
Voor de studies uitgevoerd binnen de Nijmeegse Continue Morbiditeits 
Registratie (CMR) ben ik ook verschillende mensen mijn dank verschuldigd. Naast 
alle betrokken huisartsen van de CMR en Henk van de Hoogen, wil ik hier met 
name Hans Bor nog eens heel hartelijk bedanken voor zijn inzet en plezierige 
samenwerking bij dit project. Hans, gedurende 2 a 3 jaar heb ik je herhaaldelijk 
lastig gevallen met allerlei vragen en verzoeken voor analyses. Nooit heb ik lang op 
een antwoord hoeven wachten. Dank daarvoor. 
Bij de dataverzameling van het tweede deel van dit proefschrift ben ik vele, 
vele mensen mijn dank verschuldigd. Alle verpleegkundigen van het onderzoek 
“Stress en Psoriasis”: Annelies Pietersen, Lisa Zimmerman, Rita Smits, Adriane 
Meijer-Marcu, en Marisol Kooijmans-Otero dank voor jullie inzet om bij alle 
deelnemers keer op keer bloed te prikken en de psoriasis in kaart te brengen. 
Tevens wil ik Annelies bedanken voor haar enorme morele steun. Het was jammer 
dat je het project niet helemaal af kon maken, maar zoals je weet was Lisa zowel 
voor het onderzoeksteam als voor de deelnemende patiënten een waardige 
vervangster. Jullie beide ben ik veel dank verschuldigd. Voor dit project ben ik 
tevens mijn dank verschuldigd aan de stagiaires: Arno Beugels, Joyce Lambrichs, 
Suzanne de Klerk,  Irene Vermeulen, en Sarah Rösener. Vol inzet hebben jullie, 
samen met de psychologisch medewerkers Liset Vos-van der Ven, Martina Baecke 
en Dore Broekhuis, meegewerkt aan de data verzameling. Hiervoor hebben jullie 
honderden afspraken met de deelnemende patiënten in goede banen geleid.  
Dank jullie wel, allemaal! 
Ook zou ik alle collega’s van de afdeling Medische Psychologie willen bedanken 
voor de leuke en gezellige jaren. De maandagmorgentaart was vaak een gezellige 
en welkome afwisseling van de schrijf- en analyse werkzaamheden. Een woord 
van dank speciaal voor de dames van het secretariaat: Nancy, Helma, Jacintha. 
Dank voor jullie praktische hulp en luisterend oor. Vooral Nancy zou ik hierbij nog 
eens extra willen bedanken voor haar inzet: het versturen van een grote enquête 
(inclusief alle brieven vouwen, enveloppen dichtplakken, etc), telefoonnummers 
opzoeken, honderden afspraken invoeren in ROCS en bij het merendeel van deze 
afspraken ook nog eens zelf de koffie inschenken voor alle deelnemers, niets was je 
te veel. Dank hiervoor.
Op deze plaats natuurlijk ook aandacht voor mijn mede junior 
onderzoekers, en dan met name mijn kamergenoten. De afgelopen jaren hebben 
we lief en leed met elkaar gedeeld en jullie hebben van zeer dicht bij mijn promotie 
onderzoek meegemaakt. Dank voor jullie luisterende oren en hulp. Een ieder 
van jullie, veel succes bij het schrijven van jullie eigen proefschriften en andere 
werkzaamheden!
En als laatste, een heel groot woord van dank aan ouders, vrienden en familie.  
Bij vele van jullie heb ik regelmatig mijn hart kunnen luchten. Dank jullie wel! Twee 
van jullie zou ik er graag even speciaal willen uitlichten. Marinda, grote zus, dank 
voor de prachtige vormgeving van dit boekje. Maar toch vooral dank aan jou, Ronny. 
Een proefschrift schrijven kost tijd, veel tijd. Hierdoor raakte de afgelopen jaren de 
balans tussen werk en privé soms wat zoek. Ik wil je ontzettend bedanken voor al je 
steun in de afgelopen jaren, op velerlei manieren. Zoals je weet waren een aantal 
vrouwelijke collega’s van mij soms best jaloers op de superlekkere maaltijden die jij 
iedere keer  weer op tafel toverde. Het scheelde mij tijd en was tevens een lokkertje 
om te zorgen dat ik nog enigszins op tijd naar huis kwam. Ook  bedankt voor het 
geduld waarmee je hebt toegestaan dat ik vele ‘vrije’ uurtjes besteedde aan mijn 
onderzoek. Maar nu is het dan eindelijk klaar! 
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de propedeuse psychologie behaald te hebben aan de Vrije Universiteit van 
Amsterdam, vervolgde zij haar universitaire opleiding psychologie aan de 
Katholieke Universiteit Nijmegen, met als afstudeerrichting Neuro- en Revalidatie 
Psychologie. Deze opleiding werd in 2003 afgerond. In datzelfde jaar begon zij 
als junior onderzoeker aan haar promotie onderzoek op de afdeling Medische 
Psychologie van het UMC St Radboud wat geresulteerd heeft in dit proefschrift. 
Het promotieonderzoek maakte deel uit van de onderzoeksschool Experimentele 
Psychopathologie (EPP) en het Nijmegen Centre for Evidence Based Practice 
(NCEBP). Tijdens haar aanstelling als junior onderzoeker is ze tevens lid geweest 
van de  promovendi council van het Nijmegen Centre for Evidence Based Practice 
(NCEBP) en is zij werkzaam geweest bij het Academisch Schijfcentrum Nijmegen 
van de Radboud Universiteit Nijmegen. Lisette Verhoeven is getrouwd met  
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